PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
29946343-3	2018	Here, we show that the prenylated chalcone, xanthohumol (XN), induces beiging of white adipocytes, stimulates lipolysis, and inhibits adipogenesis of murine 3T3-L1 adipocytes and primary human subcutaneous preadipocytes and these effects are partly mediated by the activation of the AMP-activated protein kinase (AMPK) signaling pathway.	xanthohumol	44-55	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	283-311
29516522-7	2018	In addition, xanthohumol treatment significantly increased the expression of genes associated with osteoblast differentiation (alkaline phosphatase, osteocalcin, osteoprotegerin and osterix).	xanthohumol	13-24	bone gamma-carboxyglutamate protein 2	Mus musculus	149-160
29516522-7	2018	In addition, xanthohumol treatment significantly increased the expression of genes associated with osteoblast differentiation (alkaline phosphatase, osteocalcin, osteoprotegerin and osterix).	xanthohumol	13-24	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	162-177
29516522-7	2018	In addition, xanthohumol treatment significantly increased the expression of genes associated with osteoblast differentiation (alkaline phosphatase, osteocalcin, osteoprotegerin and osterix).	xanthohumol	13-24	Sp7 transcription factor 7	Mus musculus	182-189
29946343-3	2018	Here, we show that the prenylated chalcone, xanthohumol (XN), induces beiging of white adipocytes, stimulates lipolysis, and inhibits adipogenesis of murine 3T3-L1 adipocytes and primary human subcutaneous preadipocytes and these effects are partly mediated by the activation of the AMP-activated protein kinase (AMPK) signaling pathway.	xanthohumol	44-55	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	313-317
29946343-3	2018	Here, we show that the prenylated chalcone, xanthohumol (XN), induces beiging of white adipocytes, stimulates lipolysis, and inhibits adipogenesis of murine 3T3-L1 adipocytes and primary human subcutaneous preadipocytes and these effects are partly mediated by the activation of the AMP-activated protein kinase (AMPK) signaling pathway.	xanthohumol	57-59	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	283-311
29946343-3	2018	Here, we show that the prenylated chalcone, xanthohumol (XN), induces beiging of white adipocytes, stimulates lipolysis, and inhibits adipogenesis of murine 3T3-L1 adipocytes and primary human subcutaneous preadipocytes and these effects are partly mediated by the activation of the AMP-activated protein kinase (AMPK) signaling pathway.	xanthohumol	57-59	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	313-317
29946343-9	2018	XN activated AMPK and in turn, XN-induced upregulation of UCP1, p-ACC, HSL, and ATGL was downregulated in the presence of dorsomorphin.	xanthohumol	0-2	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	13-17
29946343-9	2018	XN activated AMPK and in turn, XN-induced upregulation of UCP1, p-ACC, HSL, and ATGL was downregulated in the presence of dorsomorphin.	xanthohumol	0-2	uncoupling protein 1	Homo sapiens	58-62
29946343-9	2018	XN activated AMPK and in turn, XN-induced upregulation of UCP1, p-ACC, HSL, and ATGL was downregulated in the presence of dorsomorphin.	xanthohumol	0-2	lipase E, hormone sensitive type	Homo sapiens	71-74
29946343-9	2018	XN activated AMPK and in turn, XN-induced upregulation of UCP1, p-ACC, HSL, and ATGL was downregulated in the presence of dorsomorphin.	xanthohumol	0-2	patatin like phospholipase domain containing 2	Homo sapiens	80-84
29946343-9	2018	XN activated AMPK and in turn, XN-induced upregulation of UCP1, p-ACC, HSL, and ATGL was downregulated in the presence of dorsomorphin.	xanthohumol	31-33	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	13-17
29946343-9	2018	XN activated AMPK and in turn, XN-induced upregulation of UCP1, p-ACC, HSL, and ATGL was downregulated in the presence of dorsomorphin.	xanthohumol	31-33	uncoupling protein 1	Homo sapiens	58-62
29946343-9	2018	XN activated AMPK and in turn, XN-induced upregulation of UCP1, p-ACC, HSL, and ATGL was downregulated in the presence of dorsomorphin.	xanthohumol	31-33	lipase E, hormone sensitive type	Homo sapiens	71-74
29946343-9	2018	XN activated AMPK and in turn, XN-induced upregulation of UCP1, p-ACC, HSL, and ATGL was downregulated in the presence of dorsomorphin.	xanthohumol	31-33	patatin like phospholipase domain containing 2	Homo sapiens	80-84
29946343-12	2018	The anti-obesity effects of XN are partly mediated by AMPK signaling pathway suggesting that XN may have potential therapeutic implications for obesity.	xanthohumol	28-30	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	54-58
29946343-12	2018	The anti-obesity effects of XN are partly mediated by AMPK signaling pathway suggesting that XN may have potential therapeutic implications for obesity.	xanthohumol	93-95	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	54-58
28940469-5	2018	In addition, xanthohumol increased glyoxalase I activity, glutathione, heme oxygenase-1 and nuclear factor erythroid 2-related factor 2 levels in the presence of MG. Pretreatment with xanthohumol before MG exposure reduced MG-induced mitochondrial dysfunction.	xanthohumol	13-24	glyoxalase 1	Mus musculus	35-47
30023810-4	2018	Honokiol, magnolol, CAPE, xanthohumol, and anacardic acid activated the MDR1 promoter in LS174T cells, and the cellular uptake of rhodamine 123 and calcein-AM, fluorescent substrates of P-glycoprotein, decreased in polyphenol-treated LS174T cells.	xanthohumol	26-37	ATP binding cassette subfamily B member 1	Homo sapiens	72-76
30023810-4	2018	Honokiol, magnolol, CAPE, xanthohumol, and anacardic acid activated the MDR1 promoter in LS174T cells, and the cellular uptake of rhodamine 123 and calcein-AM, fluorescent substrates of P-glycoprotein, decreased in polyphenol-treated LS174T cells.	xanthohumol	26-37	ATP binding cassette subfamily B member 1	Homo sapiens	186-200
28539058-4	2018	Xanthohumol (10 mug/mL) displayed the highest (p < 0.05) percentage of neurite-bearing PC12 Adh cells and the highest (p < 0.05) NGF level in the culture medium of xanthohumol-treated cells.	xanthohumol	0-11	nerve growth factor	Rattus norvegicus	135-138
29670521-3	2018	The ELISA and Western-blot analysis revealed that xanthohumol (Xn) inhibited Abeta accumulation and APP processing, and that Xn ameliorated tau hyperphosphorylation via PP2A, GSK3beta pathways in N2a/APP cells.	xanthohumol	125-127	protein phosphatase 2, regulatory subunit A, alpha	Mus musculus	169-173
29670521-3	2018	The ELISA and Western-blot analysis revealed that xanthohumol (Xn) inhibited Abeta accumulation and APP processing, and that Xn ameliorated tau hyperphosphorylation via PP2A, GSK3beta pathways in N2a/APP cells.	xanthohumol	125-127	glycogen synthase kinase 3 beta	Mus musculus	175-183
28940469-5	2018	In addition, xanthohumol increased glyoxalase I activity, glutathione, heme oxygenase-1 and nuclear factor erythroid 2-related factor 2 levels in the presence of MG. Pretreatment with xanthohumol before MG exposure reduced MG-induced mitochondrial dysfunction.	xanthohumol	13-24	heme oxygenase 1	Mus musculus	71-135
28940469-7	2018	Notably, the autophagy-reducing effect of xanthohumol was abolished after the addition of Ex527, a selective inhibitor of sirtuin 1, suggesting that xanthohumol is an effective sirtuin 1 activator for reducing autophagy.	xanthohumol	42-53	sirtuin 1	Mus musculus	122-131
28940469-7	2018	Notably, the autophagy-reducing effect of xanthohumol was abolished after the addition of Ex527, a selective inhibitor of sirtuin 1, suggesting that xanthohumol is an effective sirtuin 1 activator for reducing autophagy.	xanthohumol	42-53	sirtuin 1	Mus musculus	177-186
28940469-7	2018	Notably, the autophagy-reducing effect of xanthohumol was abolished after the addition of Ex527, a selective inhibitor of sirtuin 1, suggesting that xanthohumol is an effective sirtuin 1 activator for reducing autophagy.	xanthohumol	149-160	sirtuin 1	Mus musculus	122-131
28940469-7	2018	Notably, the autophagy-reducing effect of xanthohumol was abolished after the addition of Ex527, a selective inhibitor of sirtuin 1, suggesting that xanthohumol is an effective sirtuin 1 activator for reducing autophagy.	xanthohumol	149-160	sirtuin 1	Mus musculus	177-186
29121426-0	2018	Xanthohumol inhibits angiogenesis by suppressing nuclear factor-kappaB activation in pancreatic cancer.	xanthohumol	0-11	nuclear factor kappa B subunit 1	Homo sapiens	49-70
29121426-4	2018	In this study, we investigated whether xanthohumol inhibited angiogenesis by blocking NF-kappaB activation in pancreatic cancer in vitro and in vivo.	xanthohumol	39-50	nuclear factor kappa B subunit 1	Homo sapiens	86-95
29121426-5	2018	We initially confirmed that xanthohumol significantly inhibited proliferation and NF-kappaB activation in pancreatic cancer cell lines.	xanthohumol	28-39	nuclear factor kappa B subunit 1	Homo sapiens	82-91
29121426-9	2018	Immunohistochemistry revealed that xanthohumol inhibited Ki-67 expression, CD31-positive microvessel density, NF-kappaB p65 expression, and VEGF and IL-8 levels.	xanthohumol	35-46	platelet and endothelial cell adhesion molecule 1	Homo sapiens	75-79
29121426-9	2018	Immunohistochemistry revealed that xanthohumol inhibited Ki-67 expression, CD31-positive microvessel density, NF-kappaB p65 expression, and VEGF and IL-8 levels.	xanthohumol	35-46	RELA proto-oncogene, NF-kB subunit	Homo sapiens	110-123
29121426-9	2018	Immunohistochemistry revealed that xanthohumol inhibited Ki-67 expression, CD31-positive microvessel density, NF-kappaB p65 expression, and VEGF and IL-8 levels.	xanthohumol	35-46	vascular endothelial growth factor A	Homo sapiens	140-144
29121426-9	2018	Immunohistochemistry revealed that xanthohumol inhibited Ki-67 expression, CD31-positive microvessel density, NF-kappaB p65 expression, and VEGF and IL-8 levels.	xanthohumol	35-46	C-X-C motif chemokine ligand 8	Homo sapiens	149-153
29121426-10	2018	Taken together, these results showed, for the first time, that xanthohumol inhibited angiogenesis by suppressing NF-kappaB activity in pancreatic cancer.	xanthohumol	63-74	nuclear factor kappa B subunit 1	Homo sapiens	113-122
29416662-0	2018	Xanthohumol prevents dextran sulfate sodium-induced colitis via inhibition of IKKbeta/NF-kappaB signaling in mice.	xanthohumol	0-11	inhibitor of kappaB kinase beta	Mus musculus	78-85
29138867-3	2018	We explored the effect of XN on Th1/Th2 balance and the underlying mechanism based on a BALB/c-4T1 breast cancer mouse model.	xanthohumol	26-28	negative elongation factor complex member C/D, Th1l	Mus musculus	32-35
29138867-9	2018	Furthermore, we found that XN significantly promoted the phosphorylation of signal transducer and activator of transcription (STAT)4.	xanthohumol	27-29	signal transducer and activator of transcription 4	Mus musculus	126-132
29422966-0	2018	Inhibition of breast cancer cell survival by Xanthohumol via modulation of the Notch signaling pathway in vivo and in vitro.	xanthohumol	45-56	notch receptor 1	Homo sapiens	79-84
29416662-8	2018	Consistently, our docking analysis revealed that XN could bind to the active site, presumably at the Cys99 of IKKbeta.	xanthohumol	49-51	inhibitor of kappaB kinase beta	Mus musculus	110-117
28501703-6	2017	In addition, protein expression and lecithin-cholesterol acyltransferase activity in the HDL fraction were significantly higher in xanthohumol-fed hamsters compared with the control, suggesting that xanthohumol promoted HDL maturation.	xanthohumol	131-142	lecithin-cholesterol acyltransferase	Homo sapiens	36-72
28858767-3	2017	In the present study, 39 bisaryl-1,4-dien-3-one compounds with 5-carbon connection chains were designed and synthesized as MD2 inhibitors based on the analysis of the molecular docking of xanthohumol to MD2.	xanthohumol	188-199	lymphocyte antigen 96	Homo sapiens	123-126
28858767-3	2017	In the present study, 39 bisaryl-1,4-dien-3-one compounds with 5-carbon connection chains were designed and synthesized as MD2 inhibitors based on the analysis of the molecular docking of xanthohumol to MD2.	xanthohumol	188-199	lymphocyte antigen 96	Homo sapiens	203-206
29152142-7	2017	Xanthohumol induced cell cycle arrest as well as apoptosis through the reduction of cell cycle regulatory proteins as well as an increase in pro-apoptotic markers (cleaved poly ADP ribose polymerase, cleaved caspase-3) and a decrease in anti-apoptotic markers (X-linked inhibitor of apoptosis and survivin).	xanthohumol	0-11	poly(ADP-ribose) polymerase 1	Homo sapiens	172-198
29152142-7	2017	Xanthohumol induced cell cycle arrest as well as apoptosis through the reduction of cell cycle regulatory proteins as well as an increase in pro-apoptotic markers (cleaved poly ADP ribose polymerase, cleaved caspase-3) and a decrease in anti-apoptotic markers (X-linked inhibitor of apoptosis and survivin).	xanthohumol	0-11	X-linked inhibitor of apoptosis	Homo sapiens	261-292
28812343-0	2017	Xanthohumol Suppresses Mylip/Idol Gene Expression and Modulates LDLR Abundance and Activity in HepG2 Cells.	xanthohumol	0-11	myosin regulatory light chain interacting protein	Homo sapiens	23-28
28812343-0	2017	Xanthohumol Suppresses Mylip/Idol Gene Expression and Modulates LDLR Abundance and Activity in HepG2 Cells.	xanthohumol	0-11	myosin regulatory light chain interacting protein	Homo sapiens	29-33
28812343-0	2017	Xanthohumol Suppresses Mylip/Idol Gene Expression and Modulates LDLR Abundance and Activity in HepG2 Cells.	xanthohumol	0-11	low density lipoprotein receptor	Homo sapiens	64-68
28812343-3	2017	We found that xanthohumol (10 and 20 muM) increased the amount of cell-surface low-density lipoprotein receptor (LDLR) from 100.0 +- 2.1% to 115.0 +- 1.3% and 135.2 +- 2.7%, and enhanced the LDL uptake activity from 100.0 +- 0.9% to 139.1 +- 13.2% in HepG2 cells (p < 0.01).	xanthohumol	14-25	latexin	Homo sapiens	37-40
28812343-3	2017	We found that xanthohumol (10 and 20 muM) increased the amount of cell-surface low-density lipoprotein receptor (LDLR) from 100.0 +- 2.1% to 115.0 +- 1.3% and 135.2 +- 2.7%, and enhanced the LDL uptake activity from 100.0 +- 0.9% to 139.1 +- 13.2% in HepG2 cells (p < 0.01).	xanthohumol	14-25	low density lipoprotein receptor	Homo sapiens	79-111
28812343-3	2017	We found that xanthohumol (10 and 20 muM) increased the amount of cell-surface low-density lipoprotein receptor (LDLR) from 100.0 +- 2.1% to 115.0 +- 1.3% and 135.2 +- 2.7%, and enhanced the LDL uptake activity from 100.0 +- 0.9% to 139.1 +- 13.2% in HepG2 cells (p < 0.01).	xanthohumol	14-25	low density lipoprotein receptor	Homo sapiens	113-117
28812343-5	2017	Xanthohumol (20 muM) reduced the expression of inducible degrader of the LDL receptor (Mylip/Idol) mRNA and protein by approximately 45% (p < 0.01), which was reported to be associated with increases of LDLR level.	xanthohumol	0-11	latexin	Homo sapiens	16-19
28812343-5	2017	Xanthohumol (20 muM) reduced the expression of inducible degrader of the LDL receptor (Mylip/Idol) mRNA and protein by approximately 45% (p < 0.01), which was reported to be associated with increases of LDLR level.	xanthohumol	0-11	myosin regulatory light chain interacting protein	Homo sapiens	47-85
28812343-5	2017	Xanthohumol (20 muM) reduced the expression of inducible degrader of the LDL receptor (Mylip/Idol) mRNA and protein by approximately 45% (p < 0.01), which was reported to be associated with increases of LDLR level.	xanthohumol	0-11	myosin regulatory light chain interacting protein	Homo sapiens	87-92
28812343-5	2017	Xanthohumol (20 muM) reduced the expression of inducible degrader of the LDL receptor (Mylip/Idol) mRNA and protein by approximately 45% (p < 0.01), which was reported to be associated with increases of LDLR level.	xanthohumol	0-11	myosin regulatory light chain interacting protein	Homo sapiens	93-97
28812343-5	2017	Xanthohumol (20 muM) reduced the expression of inducible degrader of the LDL receptor (Mylip/Idol) mRNA and protein by approximately 45% (p < 0.01), which was reported to be associated with increases of LDLR level.	xanthohumol	0-11	low density lipoprotein receptor	Homo sapiens	206-210
28812343-6	2017	We demonstrated that xanthohumol suppressed hepatic Mylip/Idol expression via counteracting liver X receptor (LXR) activation.	xanthohumol	21-32	myosin regulatory light chain interacting protein	Homo sapiens	52-57
28812343-6	2017	We demonstrated that xanthohumol suppressed hepatic Mylip/Idol expression via counteracting liver X receptor (LXR) activation.	xanthohumol	21-32	myosin regulatory light chain interacting protein	Homo sapiens	58-62
28812343-7	2017	The molecular docking results predicted that xanthohumol has a high binding affinity to interact with the LXRalpha ligand-binding domain, which may result in attenuation of LXRalpha-induced Mylip/Idol expression.	xanthohumol	45-56	nuclear receptor subfamily 1 group H member 3	Homo sapiens	106-114
28812343-7	2017	The molecular docking results predicted that xanthohumol has a high binding affinity to interact with the LXRalpha ligand-binding domain, which may result in attenuation of LXRalpha-induced Mylip/Idol expression.	xanthohumol	45-56	nuclear receptor subfamily 1 group H member 3	Homo sapiens	173-181
28812343-7	2017	The molecular docking results predicted that xanthohumol has a high binding affinity to interact with the LXRalpha ligand-binding domain, which may result in attenuation of LXRalpha-induced Mylip/Idol expression.	xanthohumol	45-56	myosin regulatory light chain interacting protein	Homo sapiens	190-195
28812343-7	2017	The molecular docking results predicted that xanthohumol has a high binding affinity to interact with the LXRalpha ligand-binding domain, which may result in attenuation of LXRalpha-induced Mylip/Idol expression.	xanthohumol	45-56	myosin regulatory light chain interacting protein	Homo sapiens	196-200
28812343-8	2017	Finally, we demonstrated that the Mylip/Idol expression and LDLR activity were synergistically changed by a combination of xanthohumol and simvastatin treatment.	xanthohumol	123-134	myosin regulatory light chain interacting protein	Homo sapiens	34-39
28812343-8	2017	Finally, we demonstrated that the Mylip/Idol expression and LDLR activity were synergistically changed by a combination of xanthohumol and simvastatin treatment.	xanthohumol	123-134	myosin regulatory light chain interacting protein	Homo sapiens	40-44
28812343-8	2017	Finally, we demonstrated that the Mylip/Idol expression and LDLR activity were synergistically changed by a combination of xanthohumol and simvastatin treatment.	xanthohumol	123-134	low density lipoprotein receptor	Homo sapiens	60-64
28501703-6	2017	In addition, protein expression and lecithin-cholesterol acyltransferase activity in the HDL fraction were significantly higher in xanthohumol-fed hamsters compared with the control, suggesting that xanthohumol promoted HDL maturation.	xanthohumol	199-210	lecithin-cholesterol acyltransferase	Homo sapiens	36-72
27494895-0	2016	Hop derived flavonoid xanthohumol inhibits endothelial cell functions via AMPK activation.	xanthohumol	22-33	HOP homeobox	Homo sapiens	0-3
28285192-0	2017	Xanthohumol ameliorates lipopolysaccharide (LPS)-induced acute lung injury via induction of AMPK/GSK3beta-Nrf2 signal axis.	xanthohumol	0-11	glycogen synthase kinase 3 beta	Mus musculus	97-110
28415750-0	2017	Xanthohumol induces paraptosis of leukemia cells through p38 mitogen activated protein kinase signaling pathway.	xanthohumol	0-11	mitogen-activated protein kinase 14	Homo sapiens	57-60
28415750-7	2017	Intriguingly, XN treatment triggered the dilatation of endoplasma reticulum (ER) and induced ER stress by upregulating C/EBP homologous protein and unfolded protein response regulator Grp78/Bip.	xanthohumol	14-16	heat shock protein family A (Hsp70) member 5	Homo sapiens	184-189
28415750-7	2017	Intriguingly, XN treatment triggered the dilatation of endoplasma reticulum (ER) and induced ER stress by upregulating C/EBP homologous protein and unfolded protein response regulator Grp78/Bip.	xanthohumol	14-16	heat shock protein family A (Hsp70) member 5	Homo sapiens	190-193
28415750-9	2017	In conclusion, we for the first time demonstrated that XN treatment can induce paraptosis of leukemia cells through activation of p38 MAPK signaling.	xanthohumol	55-57	mitogen-activated protein kinase 14	Homo sapiens	130-133
28122154-0	2017	Protein kinase A inhibition facilitates the antitumor activity of xanthohumol, a valosin-containing protein inhibitor.	xanthohumol	66-77	valosin containing protein	Homo sapiens	81-107
28105237-3	2016	The effects of xanthohumol on the cell viability and apoptosis rate of laryngeal squamous cell carcinoma SCC4 cells were assessed by Annexin V-fluorescein isothiocyanate/propidium iodide staining.	xanthohumol	15-26	MAU2 sister chromatid cohesion factor	Homo sapiens	105-109
28105237-3	2016	The effects of xanthohumol on the cell viability and apoptosis rate of laryngeal squamous cell carcinoma SCC4 cells were assessed by Annexin V-fluorescein isothiocyanate/propidium iodide staining.	xanthohumol	15-26	annexin A5	Homo sapiens	133-142
28105237-5	2016	The results revealed that treatment with 40 microM xanthohumol significantly inhibited the proliferation of SCC4 cells.	xanthohumol	51-62	MAU2 sister chromatid cohesion factor	Homo sapiens	108-112
28105237-6	2016	Furthermore, xanthohumol treatment (40 microM) induced SCC4 cell apoptosis, as indicated by the significant increase in activity and expression of caspase-3, caspase-8, caspase-9, PARP, p53 and AIF.	xanthohumol	13-24	MAU2 sister chromatid cohesion factor	Homo sapiens	55-59
28105237-6	2016	Furthermore, xanthohumol treatment (40 microM) induced SCC4 cell apoptosis, as indicated by the significant increase in activity and expression of caspase-3, caspase-8, caspase-9, PARP, p53 and AIF.	xanthohumol	13-24	caspase 3	Homo sapiens	147-156
28105237-6	2016	Furthermore, xanthohumol treatment (40 microM) induced SCC4 cell apoptosis, as indicated by the significant increase in activity and expression of caspase-3, caspase-8, caspase-9, PARP, p53 and AIF.	xanthohumol	13-24	caspase 8	Homo sapiens	158-167
28105237-6	2016	Furthermore, xanthohumol treatment (40 microM) induced SCC4 cell apoptosis, as indicated by the significant increase in activity and expression of caspase-3, caspase-8, caspase-9, PARP, p53 and AIF.	xanthohumol	13-24	caspase 9	Homo sapiens	169-178
28105237-6	2016	Furthermore, xanthohumol treatment (40 microM) induced SCC4 cell apoptosis, as indicated by the significant increase in activity and expression of caspase-3, caspase-8, caspase-9, PARP, p53 and AIF.	xanthohumol	13-24	poly(ADP-ribose) polymerase 1	Homo sapiens	180-184
28105237-6	2016	Furthermore, xanthohumol treatment (40 microM) induced SCC4 cell apoptosis, as indicated by the significant increase in activity and expression of caspase-3, caspase-8, caspase-9, PARP, p53 and AIF.	xanthohumol	13-24	tumor protein p53	Homo sapiens	186-189
28105237-6	2016	Furthermore, xanthohumol treatment (40 microM) induced SCC4 cell apoptosis, as indicated by the significant increase in activity and expression of caspase-3, caspase-8, caspase-9, PARP, p53 and AIF.	xanthohumol	13-24	apoptosis inducing factor mitochondria associated 1	Homo sapiens	194-197
28105237-7	2016	By contrast, the protein expression of Bcl-2 and Mcl-1 was significantly decreased following treatment with 40 microM xanthohumol.	xanthohumol	118-129	BCL2 apoptosis regulator	Homo sapiens	39-44
28105237-7	2016	By contrast, the protein expression of Bcl-2 and Mcl-1 was significantly decreased following treatment with 40 microM xanthohumol.	xanthohumol	118-129	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	49-54
28105237-8	2016	Taken together, the results of the present study indicated that xanthohumol mediates growth suppression and apoptosis induction, which was mediated via the suppression of Bcl-2 and Mcl-1 and activation of PARP, p53 and AIF signaling pathways.	xanthohumol	64-75	BCL2 apoptosis regulator	Homo sapiens	171-176
28105237-8	2016	Taken together, the results of the present study indicated that xanthohumol mediates growth suppression and apoptosis induction, which was mediated via the suppression of Bcl-2 and Mcl-1 and activation of PARP, p53 and AIF signaling pathways.	xanthohumol	64-75	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	181-186
28105237-8	2016	Taken together, the results of the present study indicated that xanthohumol mediates growth suppression and apoptosis induction, which was mediated via the suppression of Bcl-2 and Mcl-1 and activation of PARP, p53 and AIF signaling pathways.	xanthohumol	64-75	poly(ADP-ribose) polymerase 1	Homo sapiens	205-209
28105237-8	2016	Taken together, the results of the present study indicated that xanthohumol mediates growth suppression and apoptosis induction, which was mediated via the suppression of Bcl-2 and Mcl-1 and activation of PARP, p53 and AIF signaling pathways.	xanthohumol	64-75	tumor protein p53	Homo sapiens	211-214
28105237-8	2016	Taken together, the results of the present study indicated that xanthohumol mediates growth suppression and apoptosis induction, which was mediated via the suppression of Bcl-2 and Mcl-1 and activation of PARP, p53 and AIF signaling pathways.	xanthohumol	64-75	apoptosis inducing factor mitochondria associated 1	Homo sapiens	219-222
27487563-0	2016	The miR-204-3p-targeted IGFBP2 pathway is involved in xanthohumol-induced glioma cell apoptotic death.	xanthohumol	54-65	insulin like growth factor binding protein 2	Homo sapiens	24-30
27487563-7	2016	We also identified that pro-caspase-9 cleavage, Bcl2 family expression changes, mitochondrial dysfunction, and intracellular ROS generation also participated in XN-induced glioma cell death.	xanthohumol	161-163	BCL2 apoptosis regulator	Homo sapiens	48-52
27921359-0	2017	Modulation of VEGF signaling in a mouse model of diabetes by xanthohumol and 8-prenylnaringenin: Unveiling the angiogenic paradox and metabolism interplay.	xanthohumol	61-72	vascular endothelial growth factor A	Mus musculus	14-18
27921359-6	2017	XN consumption reduced angiogenesis, VEGFR-2 expression/activity, VEGF-A and phosphofructokinase-2/fructose-2,6-bisphosphatase-3 enzyme expression, a metabolic marker present in endothelial tip cells in T2DM mice kidney.	xanthohumol	0-2	kinase insert domain protein receptor	Mus musculus	37-44
27921359-6	2017	XN consumption reduced angiogenesis, VEGFR-2 expression/activity, VEGF-A and phosphofructokinase-2/fructose-2,6-bisphosphatase-3 enzyme expression, a metabolic marker present in endothelial tip cells in T2DM mice kidney.	xanthohumol	0-2	vascular endothelial growth factor A	Mus musculus	66-72
27596062-3	2016	We and others have shown that xanthohumol (XN), the principal prenylflavonoid of the hop plant (Humulus lupulus L.), is a FXR agonist based on its ability to affect lipid and glucose metabolism in vivo and to induces FXR target genes in biliary carcinoma cells and HEK293 cells.	xanthohumol	30-41	nuclear receptor subfamily 1 group H member 4	Homo sapiens	122-125
27596062-3	2016	We and others have shown that xanthohumol (XN), the principal prenylflavonoid of the hop plant (Humulus lupulus L.), is a FXR agonist based on its ability to affect lipid and glucose metabolism in vivo and to induces FXR target genes in biliary carcinoma cells and HEK293 cells.	xanthohumol	30-41	nuclear receptor subfamily 1 group H member 4	Homo sapiens	217-220
27494895-0	2016	Hop derived flavonoid xanthohumol inhibits endothelial cell functions via AMPK activation.	xanthohumol	22-33	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	74-78
27494895-5	2016	Here we investigated the involvement of AMPK in the anti-angiogenic effects of xanthohumol (XN), the major prenylated flavonoid of the hop plant, and mechanisms of action.	xanthohumol	79-90	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	40-44
27494895-7	2016	Treatment of endothelial cells with XN led to increased AMPK phosphorylation and activity.	xanthohumol	36-38	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	56-60
27494895-9	2016	AMPK activation by XN was mediated by CAMMKbeta, but not LKB1.	xanthohumol	19-21	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	0-4
27494895-10	2016	Analysis of the downstream mechanisms showed that XN-induced AMPK activation reduced nitric oxide (NO) levels in endothelial cells by decreasing eNOS phosphorylation.	xanthohumol	50-52	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	61-65
26794001-0	2016	Xanthohumol inhibits STAT3 activation pathway leading to growth suppression and apoptosis induction in human cholangiocarcinoma cells.	xanthohumol	0-11	signal transducer and activator of transcription 3	Homo sapiens	21-26
27338375-2	2016	We tested the apoptotic and cytotoxic activities of xanthohumol, a prenylated chalcone found in Humulus lupulus on androgen-sensitive human prostate adenocarcinoma cells (LNCaP) in combination with TRAIL.	xanthohumol	52-63	TNF superfamily member 10	Homo sapiens	198-203
27338375-7	2016	Our study showed that xanthohumol enhanced cytotoxic and apoptotic effects of TRAIL.	xanthohumol	22-33	TNF superfamily member 10	Homo sapiens	78-83
27338375-10	2016	The findings suggest that xanthohumol is a compound of potential use in chemoprevention of prostate cancer due to its sensitization of cancer cells to TRAIL-mediated apoptosis.	xanthohumol	26-37	TNF superfamily member 10	Homo sapiens	151-156
26976708-7	2016	Treatment with XN at 60 mg/kg/day resulted in reduced plasma LDL-cholesterol (LDL-C), IL-6, insulin and leptin levels by 80%, 78%, 42%, and 41%, respectively, compared to the vehicle control group.	xanthohumol	15-17	component of oligomeric golgi complex 2	Mus musculus	61-76
26976708-7	2016	Treatment with XN at 60 mg/kg/day resulted in reduced plasma LDL-cholesterol (LDL-C), IL-6, insulin and leptin levels by 80%, 78%, 42%, and 41%, respectively, compared to the vehicle control group.	xanthohumol	15-17	component of oligomeric golgi complex 2	Mus musculus	78-83
26976708-7	2016	Treatment with XN at 60 mg/kg/day resulted in reduced plasma LDL-cholesterol (LDL-C), IL-6, insulin and leptin levels by 80%, 78%, 42%, and 41%, respectively, compared to the vehicle control group.	xanthohumol	15-17	interleukin 6	Mus musculus	86-90
26976708-8	2016	Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) levels were 44% lower in the 60 mg/kg dose group compared to the vehicle control group (p <= 0.05) which may account for the LDL-C lowering activity of XN.	xanthohumol	205-207	proprotein convertase subtilisin/kexin type 9	Mus musculus	0-40
26976708-8	2016	Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) levels were 44% lower in the 60 mg/kg dose group compared to the vehicle control group (p <= 0.05) which may account for the LDL-C lowering activity of XN.	xanthohumol	205-207	proprotein convertase subtilisin/kexin type 9	Mus musculus	42-48
27317025-0	2016	Xanthohumol inhibits the extracellular signal regulated kinase (ERK) signalling pathway and suppresses cell growth of lung adenocarcinoma cells.	xanthohumol	0-11	mitogen-activated protein kinase 1	Homo sapiens	25-62
27317025-0	2016	Xanthohumol inhibits the extracellular signal regulated kinase (ERK) signalling pathway and suppresses cell growth of lung adenocarcinoma cells.	xanthohumol	0-11	mitogen-activated protein kinase 1	Homo sapiens	64-67
27317025-5	2016	We observed that XN was able to suppress the activities of ERK1/2 and p90RSK kinases, followed by inhibition of phosphorylation and activation of the CREB protein.	xanthohumol	17-19	mitogen-activated protein kinase 3	Homo sapiens	59-65
27317025-5	2016	We observed that XN was able to suppress the activities of ERK1/2 and p90RSK kinases, followed by inhibition of phosphorylation and activation of the CREB protein.	xanthohumol	17-19	ribosomal protein S6 kinase A1	Homo sapiens	70-76
27317025-5	2016	We observed that XN was able to suppress the activities of ERK1/2 and p90RSK kinases, followed by inhibition of phosphorylation and activation of the CREB protein.	xanthohumol	17-19	cAMP responsive element binding protein 1	Homo sapiens	150-154
27317025-7	2016	As a result, the cytotoxic effect of XN was attributed to the cell cycle arrest at G1 phase and induction of apoptosis indicated by increased caspase-3 activity.	xanthohumol	37-39	caspase 3	Homo sapiens	142-151
26794001-2	2016	Xanthohumol (XN), a prenylated flavonoid extracted from hops, has known anticancer activity and could potentially target STAT3.	xanthohumol	0-11	signal transducer and activator of transcription 3	Homo sapiens	121-126
26794001-2	2016	Xanthohumol (XN), a prenylated flavonoid extracted from hops, has known anticancer activity and could potentially target STAT3.	xanthohumol	13-15	signal transducer and activator of transcription 3	Homo sapiens	121-126
26794001-3	2016	The present study determined the effect of XN on STAT3, as well as ascertained its usefulness against CCA.	xanthohumol	43-45	signal transducer and activator of transcription 3	Homo sapiens	49-54
26794001-9	2016	The present study shows that XN can inhibit STAT3 activation both in vivo and in vitro due to suppression of the Akt-NFkappaB signaling pathway.	xanthohumol	29-31	signal transducer and activator of transcription 3	Homo sapiens	44-49
26794001-9	2016	The present study shows that XN can inhibit STAT3 activation both in vivo and in vitro due to suppression of the Akt-NFkappaB signaling pathway.	xanthohumol	29-31	AKT serine/threonine kinase 1	Homo sapiens	113-116
27904394-6	2016	A yeast yap1 deletion mutant strain sensitive to oxidative stress grew more slowly in the presence of at least 5 mg/L of xanthohumol than cultures of the wild type, suggesting that xanthohumol toxicity is mediated by oxidative stress.	xanthohumol	121-132	DNA-binding transcription factor YAP1	Saccharomyces cerevisiae S288C	8-12
27904394-6	2016	A yeast yap1 deletion mutant strain sensitive to oxidative stress grew more slowly in the presence of at least 5 mg/L of xanthohumol than cultures of the wild type, suggesting that xanthohumol toxicity is mediated by oxidative stress.	xanthohumol	181-192	DNA-binding transcription factor YAP1	Saccharomyces cerevisiae S288C	8-12
26620037-3	2015	In this study, we examined the effects of xanthohumol (XN), an abundant prenylflavonoid from hops plant, on osteoclastogenesis, osteoclast resorption, and RANKL-induced signaling pathway using both in vitro and in vivo assay systems.	xanthohumol	42-53	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	155-160
26718026-0	2016	Anticancer effect of xanthohumol induces growth inhibition and apoptosis of human liver cancer through NF-kappaB/p53-apoptosis signaling pathway.	xanthohumol	21-32	tumor protein p53	Homo sapiens	113-116
26718026-2	2016	We investigate whether the anticancer effect of xanthohumol induces growth inhibition and apoptosis of human liver cancer through NF-kappaB/p53-apoptosis signaling pathway.	xanthohumol	48-59	tumor protein p53	Homo sapiens	140-143
26718026-4	2016	Furthermore, the caspase-3 activity of human liver cancer HepG2 cells was increased by xanthohumol.	xanthohumol	87-98	caspase 3	Homo sapiens	17-26
26718026-5	2016	In addition, 48-h treatment with xanthohumol suppressed NF-kappaB expression and promoted p53, cleaved PARP, AIF and cytochrome c expression and downregulated XIAP and Bcl-2/Bax expression in human liver cancer HepG2 cells.	xanthohumol	33-44	tumor protein p53	Homo sapiens	90-93
26718026-5	2016	In addition, 48-h treatment with xanthohumol suppressed NF-kappaB expression and promoted p53, cleaved PARP, AIF and cytochrome c expression and downregulated XIAP and Bcl-2/Bax expression in human liver cancer HepG2 cells.	xanthohumol	33-44	collagen type XI alpha 2 chain	Homo sapiens	103-107
26718026-5	2016	In addition, 48-h treatment with xanthohumol suppressed NF-kappaB expression and promoted p53, cleaved PARP, AIF and cytochrome c expression and downregulated XIAP and Bcl-2/Bax expression in human liver cancer HepG2 cells.	xanthohumol	33-44	apoptosis inducing factor mitochondria associated 1	Homo sapiens	109-112
26718026-5	2016	In addition, 48-h treatment with xanthohumol suppressed NF-kappaB expression and promoted p53, cleaved PARP, AIF and cytochrome c expression and downregulated XIAP and Bcl-2/Bax expression in human liver cancer HepG2 cells.	xanthohumol	33-44	cytochrome c, somatic	Homo sapiens	117-129
26718026-5	2016	In addition, 48-h treatment with xanthohumol suppressed NF-kappaB expression and promoted p53, cleaved PARP, AIF and cytochrome c expression and downregulated XIAP and Bcl-2/Bax expression in human liver cancer HepG2 cells.	xanthohumol	33-44	X-linked inhibitor of apoptosis	Homo sapiens	159-163
26718026-5	2016	In addition, 48-h treatment with xanthohumol suppressed NF-kappaB expression and promoted p53, cleaved PARP, AIF and cytochrome c expression and downregulated XIAP and Bcl-2/Bax expression in human liver cancer HepG2 cells.	xanthohumol	33-44	BCL2 apoptosis regulator	Homo sapiens	168-173
26718026-5	2016	In addition, 48-h treatment with xanthohumol suppressed NF-kappaB expression and promoted p53, cleaved PARP, AIF and cytochrome c expression and downregulated XIAP and Bcl-2/Bax expression in human liver cancer HepG2 cells.	xanthohumol	33-44	BCL2 associated X, apoptosis regulator	Homo sapiens	174-177
26718026-6	2016	Therefore, the anticancer effect of xanthohumol induces growth inhibition and apoptosis of human liver cancer through the NF-kappaB/p53-apoptosis signaling pathway.	xanthohumol	36-47	tumor protein p53	Homo sapiens	132-135
26869767-4	2016	Several studies have reported that xanthohumol (XN), an anti-inflammatory natural product from hops and beer, can block the TLR4 signaling by binding to MD-2 directly.	xanthohumol	35-46	toll like receptor 4	Homo sapiens	124-128
26869767-4	2016	Several studies have reported that xanthohumol (XN), an anti-inflammatory natural product from hops and beer, can block the TLR4 signaling by binding to MD-2 directly.	xanthohumol	35-46	lymphocyte antigen 96	Homo sapiens	153-157
26869767-4	2016	Several studies have reported that xanthohumol (XN), an anti-inflammatory natural product from hops and beer, can block the TLR4 signaling by binding to MD-2 directly.	xanthohumol	48-50	toll like receptor 4	Homo sapiens	124-128
26869767-4	2016	Several studies have reported that xanthohumol (XN), an anti-inflammatory natural product from hops and beer, can block the TLR4 signaling by binding to MD-2 directly.	xanthohumol	48-50	lymphocyte antigen 96	Homo sapiens	153-157
26869767-7	2016	Using a combination of experimental and theoretical modeling analysis, we found that XN can embed into the hydrophobic pocket of MD-2 and form two stable hydrogen bonds with residues ARG-90 and TYR-102 of MD-2.	xanthohumol	85-87	lymphocyte antigen 96	Homo sapiens	129-133
26869767-7	2016	Using a combination of experimental and theoretical modeling analysis, we found that XN can embed into the hydrophobic pocket of MD-2 and form two stable hydrogen bonds with residues ARG-90 and TYR-102 of MD-2.	xanthohumol	85-87	lymphocyte antigen 96	Homo sapiens	205-209
26667007-3	2016	The inhibitory effect of xanthohumol on the evoked glutamate release was prevented by removing extracellular Ca(2+), using the Cav2.2 (N-type) and Cav2.1 (P/Q-type) channel blocker omega-CgTX MVIIC, the calmodulin antagonists W7 and calmidazolium, and the protein kinase A inhibitor H89; however, no such effect was observed when the G-protein inhibitor N-ethylmaleimide was used.	xanthohumol	25-36	calcium voltage-gated channel subunit alpha1 A	Rattus norvegicus	147-153
26620037-3	2015	In this study, we examined the effects of xanthohumol (XN), an abundant prenylflavonoid from hops plant, on osteoclastogenesis, osteoclast resorption, and RANKL-induced signaling pathway using both in vitro and in vivo assay systems.	xanthohumol	55-57	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	155-160
26620037-6	2015	In ovariectomized-induced bone loss mouse model and RANKL-injection-induced bone resorption model, we found that administration of XN markedly inhibited bone loss and resorption by suppressing osteoclast activity.	xanthohumol	131-133	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	52-57
26473469-3	2015	We have previously shown that hops and its Michael acceptor xanthohumol (XH) induced the chemoprevention enzyme, NAD(P)H: quinone oxidoreductase 1 (NQO1), in vitro and in vivo.	xanthohumol	60-71	NAD(P)H dehydrogenase, quinone 1	Mus musculus	148-152
26473469-3	2015	We have previously shown that hops and its Michael acceptor xanthohumol (XH) induced the chemoprevention enzyme, NAD(P)H: quinone oxidoreductase 1 (NQO1), in vitro and in vivo.	xanthohumol	73-75	NAD(P)H dehydrogenase, quinone 1	Mus musculus	148-152
26194608-5	2015	The effect of XH (5 microM; 24 h) upon (3)H-DG uptake involved mammalian target of rapamycin, tyrosine kinases and c-Jun N-terminal kinases intracellular pathways.	xanthohumol	14-16	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	115-120
25843659-2	2015	Making use of xanthohumol (XN) as an activator of both the AMPK and the Nrf2 signaling pathway we show that AMPK exerts a positive influence on Nrf2/heme oxygenase (HO)-1 signaling in mouse embryonic fibroblasts.	xanthohumol	14-25	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	59-63
25843659-2	2015	Making use of xanthohumol (XN) as an activator of both the AMPK and the Nrf2 signaling pathway we show that AMPK exerts a positive influence on Nrf2/heme oxygenase (HO)-1 signaling in mouse embryonic fibroblasts.	xanthohumol	14-25	nuclear factor, erythroid derived 2, like 2	Mus musculus	72-76
25843659-2	2015	Making use of xanthohumol (XN) as an activator of both the AMPK and the Nrf2 signaling pathway we show that AMPK exerts a positive influence on Nrf2/heme oxygenase (HO)-1 signaling in mouse embryonic fibroblasts.	xanthohumol	14-25	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	108-112
25843659-2	2015	Making use of xanthohumol (XN) as an activator of both the AMPK and the Nrf2 signaling pathway we show that AMPK exerts a positive influence on Nrf2/heme oxygenase (HO)-1 signaling in mouse embryonic fibroblasts.	xanthohumol	14-25	NFE2 like bZIP transcription factor 2	Homo sapiens	144-148
25843659-2	2015	Making use of xanthohumol (XN) as an activator of both the AMPK and the Nrf2 signaling pathway we show that AMPK exerts a positive influence on Nrf2/heme oxygenase (HO)-1 signaling in mouse embryonic fibroblasts.	xanthohumol	27-29	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	59-63
25843659-2	2015	Making use of xanthohumol (XN) as an activator of both the AMPK and the Nrf2 signaling pathway we show that AMPK exerts a positive influence on Nrf2/heme oxygenase (HO)-1 signaling in mouse embryonic fibroblasts.	xanthohumol	27-29	nuclear factor, erythroid derived 2, like 2	Mus musculus	72-76
25843659-2	2015	Making use of xanthohumol (XN) as an activator of both the AMPK and the Nrf2 signaling pathway we show that AMPK exerts a positive influence on Nrf2/heme oxygenase (HO)-1 signaling in mouse embryonic fibroblasts.	xanthohumol	27-29	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	108-112
25843659-2	2015	Making use of xanthohumol (XN) as an activator of both the AMPK and the Nrf2 signaling pathway we show that AMPK exerts a positive influence on Nrf2/heme oxygenase (HO)-1 signaling in mouse embryonic fibroblasts.	xanthohumol	27-29	NFE2 like bZIP transcription factor 2	Homo sapiens	144-148
26297991-7	2015	The mechanisms involved in these effects of XN were associated with cell growth inhibition by induction of cell cycle arrest in the G1 phase, increased p53 and p21/WAF1 expression levels, downregulation of cyclin D1 and Bcl-2, and activation of caspases-9, -8, and -3.	xanthohumol	44-46	tumor protein p53	Homo sapiens	152-155
26297991-7	2015	The mechanisms involved in these effects of XN were associated with cell growth inhibition by induction of cell cycle arrest in the G1 phase, increased p53 and p21/WAF1 expression levels, downregulation of cyclin D1 and Bcl-2, and activation of caspases-9, -8, and -3.	xanthohumol	44-46	cyclin dependent kinase inhibitor 1A	Homo sapiens	160-163
26297991-7	2015	The mechanisms involved in these effects of XN were associated with cell growth inhibition by induction of cell cycle arrest in the G1 phase, increased p53 and p21/WAF1 expression levels, downregulation of cyclin D1 and Bcl-2, and activation of caspases-9, -8, and -3.	xanthohumol	44-46	cyclin dependent kinase inhibitor 1A	Homo sapiens	164-168
26297991-7	2015	The mechanisms involved in these effects of XN were associated with cell growth inhibition by induction of cell cycle arrest in the G1 phase, increased p53 and p21/WAF1 expression levels, downregulation of cyclin D1 and Bcl-2, and activation of caspases-9, -8, and -3.	xanthohumol	44-46	cyclin D1	Homo sapiens	206-215
26297991-7	2015	The mechanisms involved in these effects of XN were associated with cell growth inhibition by induction of cell cycle arrest in the G1 phase, increased p53 and p21/WAF1 expression levels, downregulation of cyclin D1 and Bcl-2, and activation of caspases-9, -8, and -3.	xanthohumol	44-46	BCL2 apoptosis regulator	Homo sapiens	220-225
26297991-7	2015	The mechanisms involved in these effects of XN were associated with cell growth inhibition by induction of cell cycle arrest in the G1 phase, increased p53 and p21/WAF1 expression levels, downregulation of cyclin D1 and Bcl-2, and activation of caspases-9, -8, and -3.	xanthohumol	44-46	caspase 9	Homo sapiens	245-267
26194608-6	2015	Moreover, XH appeared to decrease cellular uptake of lactate due to inhibition of the monocarboxylate transporter 1.	xanthohumol	10-12	solute carrier family 16 member 1	Homo sapiens	86-115
25688010-0	2015	Inhibition of Kv1.3 Channels in Human Jurkat T Cells by Xanthohumol and Isoxanthohumol.	xanthohumol	56-67	potassium voltage-gated channel subfamily A member 3	Homo sapiens	14-19
26664015-10	2015	Xanthohumol induced accumulation of cells in sub G1 and S phase based on cell cycle analysis and also increased the activities of caspase-3, -8, and -9.	xanthohumol	0-11	caspase 3	Homo sapiens	130-151
25688010-1	2015	Using whole-cell patch-clamp technique, we investigated influence of selected compounds from groups of prenylated chalcones and flavonoids: xanthohumol and isoxanthohumol on the activity of Kv1.3 channels in human leukemic Jurkat T cells.	xanthohumol	140-151	potassium voltage-gated channel subfamily A member 3	Homo sapiens	190-195
25999863-5	2015	Furthermore, the potential use of xanthohumol or a xanthohumol-enriched hop extract as therapeutic agent to combat the progression of chronic liver disease will be discussed.	xanthohumol	51-62	HOP homeobox	Homo sapiens	72-75
26211581-3	2015	XN treatment was found to induce cell cycle arrest and apoptosis of PC cells (PANC-1, BxPC-3) by inhibiting phosphorylation of signal transducer and activator of transcription 3 (STAT3) and expression of its downstream targeted genes cyclinD1, survivin, and Bcl-xL at the messenger RNA level, which involved in regulation of apoptosis and the cell cycle.	xanthohumol	0-2	signal transducer and activator of transcription 3	Homo sapiens	127-177
26211581-3	2015	XN treatment was found to induce cell cycle arrest and apoptosis of PC cells (PANC-1, BxPC-3) by inhibiting phosphorylation of signal transducer and activator of transcription 3 (STAT3) and expression of its downstream targeted genes cyclinD1, survivin, and Bcl-xL at the messenger RNA level, which involved in regulation of apoptosis and the cell cycle.	xanthohumol	0-2	signal transducer and activator of transcription 3	Homo sapiens	179-184
26211581-3	2015	XN treatment was found to induce cell cycle arrest and apoptosis of PC cells (PANC-1, BxPC-3) by inhibiting phosphorylation of signal transducer and activator of transcription 3 (STAT3) and expression of its downstream targeted genes cyclinD1, survivin, and Bcl-xL at the messenger RNA level, which involved in regulation of apoptosis and the cell cycle.	xanthohumol	0-2	cyclin D1	Homo sapiens	234-242
26211581-3	2015	XN treatment was found to induce cell cycle arrest and apoptosis of PC cells (PANC-1, BxPC-3) by inhibiting phosphorylation of signal transducer and activator of transcription 3 (STAT3) and expression of its downstream targeted genes cyclinD1, survivin, and Bcl-xL at the messenger RNA level, which involved in regulation of apoptosis and the cell cycle.	xanthohumol	0-2	BCL2 like 1	Homo sapiens	258-264
25999863-1	2015	Xanthohumol is the principal prenylated flavonoid of the female inflorescences of the hop plant.	xanthohumol	0-11	HOP homeobox	Homo sapiens	86-89
25887885-0	2015	Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells.	xanthohumol	0-11	notch receptor 1	Homo sapiens	36-42
25887885-7	2015	The growth suppression effect of XN in pancreatic cancer cell lines is due to increased apoptosis via the inhibition of the Notch1 signaling pathway, as evidenced by reduction in Notch1, HES-1, and survivin both at mRNA as well as protein levels.	xanthohumol	33-35	notch receptor 1	Homo sapiens	124-130
25887885-7	2015	The growth suppression effect of XN in pancreatic cancer cell lines is due to increased apoptosis via the inhibition of the Notch1 signaling pathway, as evidenced by reduction in Notch1, HES-1, and survivin both at mRNA as well as protein levels.	xanthohumol	33-35	notch receptor 1	Homo sapiens	179-185
25887885-7	2015	The growth suppression effect of XN in pancreatic cancer cell lines is due to increased apoptosis via the inhibition of the Notch1 signaling pathway, as evidenced by reduction in Notch1, HES-1, and survivin both at mRNA as well as protein levels.	xanthohumol	33-35	hes family bHLH transcription factor 1	Homo sapiens	187-192
26011160-0	2015	Xanthohumol inhibits Notch signaling and induces apoptosis in hepatocellular carcinoma.	xanthohumol	0-11	notch receptor 1	Homo sapiens	21-26
25776492-4	2015	The accumulation of daunorubicin or rhodamine 123, fluorescent substrates of P-glycoprotein, in KB/MDR1 cells increased in the presence of caffeic acid phenetyl ester (CAPE), licochalcone A, anacardic acid, celastrol, xanthohumol, magnolol, and honokiol in a concentration-dependent manner.	xanthohumol	218-229	ATP binding cassette subfamily B member 1	Homo sapiens	77-91
25776492-6	2015	The ATPase activities of P-glycoprotein were stimulated by CAPE, licochalcone A, anacardic acid, celastrol, xanthohumol, magnolol, and honokiol.	xanthohumol	108-119	ATP binding cassette subfamily B member 1	Homo sapiens	25-39
25776492-7	2015	Tumor necrosis factor (TNF)-alpha stimulated NF-kappaB activation was inhibited by CAPE, licochalcone A, anacardic acid, and xanthohumol.	xanthohumol	125-136	tumor necrosis factor	Homo sapiens	0-33
25776492-8	2015	KB/MDR1 cells were sensitized to vinblastine cytotoxicity by CAPE, licochalcone A, anacardic acid, xanthohumol, magnolol, and honokiol, showing that these natural NF-kappaB inhibitors reverse multidrug resistance.	xanthohumol	99-110	ATP binding cassette subfamily B member 1	Homo sapiens	3-7
25949267-3	2015	The present study showed that xanthohumol was effective to inhibit proliferation of Ca Ski cells based on IC50 values using sulforhodamine B (SRB) assay.	xanthohumol	30-41	chaperonin containing TCP1 subunit 4	Homo sapiens	124-140
25587858-0	2015	Xanthohumol, a polyphenol chalcone present in hops, activating Nrf2 enzymes to confer protection against oxidative damage in PC12 cells.	xanthohumol	0-11	NFE2 like bZIP transcription factor 2	Rattus norvegicus	63-67
25949267-3	2015	The present study showed that xanthohumol was effective to inhibit proliferation of Ca Ski cells based on IC50 values using sulforhodamine B (SRB) assay.	xanthohumol	30-41	chaperonin containing TCP1 subunit 4	Homo sapiens	142-145
25949267-8	2015	Taken together, these findings indicate that xanthohumol-induced cell death might involve intrinsic and extrinsic apoptotic pathways, as well as downregulation of XIAP, upregulation of p53 proteins, and S phase cell cycle arrest in Ca Ski cervical cancer cells.	xanthohumol	45-56	X-linked inhibitor of apoptosis	Homo sapiens	163-167
25949267-8	2015	Taken together, these findings indicate that xanthohumol-induced cell death might involve intrinsic and extrinsic apoptotic pathways, as well as downregulation of XIAP, upregulation of p53 proteins, and S phase cell cycle arrest in Ca Ski cervical cancer cells.	xanthohumol	45-56	tumor protein p53	Homo sapiens	185-188
24897556-0	2014	Xanthohumol, a prenylated chalcone from beer hops, acts as an alpha-glucosidase inhibitor in vitro.	xanthohumol	0-11	sucrase-isomaltase	Homo sapiens	62-79
25044854-3	2014	METHODS AND RESULTS: ABCG2-inhibitory activity of xanthohumol (XN), isoxanthohumol (IX), 6-prenylnaringenin (6-PN), 8-prenylnaringenin (8-PN), and 6,8-diprenylnarigenin (6,8-diPN) was evaluated using mitoxantrone accumulation and vesicular transport assays.	xanthohumol	50-61	ATP binding cassette subfamily G member 2	Canis lupus familiaris	21-26
25483453-0	2014	Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions.	xanthohumol	0-11	WD repeat domain 5	Homo sapiens	87-91
25483453-0	2014	Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions.	xanthohumol	0-11	prohibitin 2	Homo sapiens	92-96
25483453-1	2014	Xanthohumol (XN) is a natural anticancer compound that inhibits the proliferation of oestrogen receptor-alpha (ERalpha)-positive breast cancer cells.	xanthohumol	0-11	estrogen receptor 1	Homo sapiens	111-118
25483453-1	2014	Xanthohumol (XN) is a natural anticancer compound that inhibits the proliferation of oestrogen receptor-alpha (ERalpha)-positive breast cancer cells.	xanthohumol	13-15	estrogen receptor 1	Homo sapiens	111-118
25483453-4	2014	XN treatment effectively prevented the BIG3-PHB2 interaction, thereby releasing PHB2 to directly bind to both nuclear- and cytoplasmic ERalpha.	xanthohumol	0-2	WD repeat domain 5	Homo sapiens	39-43
25483453-4	2014	XN treatment effectively prevented the BIG3-PHB2 interaction, thereby releasing PHB2 to directly bind to both nuclear- and cytoplasmic ERalpha.	xanthohumol	0-2	prohibitin 2	Homo sapiens	44-48
25483453-4	2014	XN treatment effectively prevented the BIG3-PHB2 interaction, thereby releasing PHB2 to directly bind to both nuclear- and cytoplasmic ERalpha.	xanthohumol	0-2	prohibitin 2	Homo sapiens	80-84
25483453-4	2014	XN treatment effectively prevented the BIG3-PHB2 interaction, thereby releasing PHB2 to directly bind to both nuclear- and cytoplasmic ERalpha.	xanthohumol	0-2	estrogen receptor 1	Homo sapiens	135-142
26842182-5	2014	RESULTS: The survival rate of the MDA-MB231 cells treated with 10 muM and 20 muM xanthohumol for 48 h decreased significantly by 64.7 +- 1.8% and 40.1 +- 1.8%, respectively.	xanthohumol	81-92	latexin	Homo sapiens	77-80
26842182-6	2014	The numbers of SubG0/G1 cells in the group treated with 10 muM and 20 muM xanthohumol increased significantly to 11.3 +- 0.2 and 18.4 +- 0.1, respectively.	xanthohumol	74-85	latexin	Homo sapiens	70-73
26842182-8	2014	Xanthohumol increased the expression of Bax in the mitochondria, which correspondingly decreased in the cytoplasm.	xanthohumol	0-11	BCL2 associated X, apoptosis regulator	Homo sapiens	40-43
24897556-3	2014	In the present study, a series of in vitro experiments were performed to investigate whether XN was an effective inhibitor of alpha-glucosidase.	xanthohumol	93-95	sucrase-isomaltase	Homo sapiens	126-143
24897556-4	2014	The results showed that XN inhibited alpha-glucosidase in a reversible and noncompetitive manner, with an IC50 value of 8.8 muM and that XN inhibited the release of glucose from the maltose in the apical side of the Caco-2 cell monolayer.	xanthohumol	24-26	sucrase-isomaltase	Homo sapiens	37-54
24897556-6	2014	These results demonstrated that XN is a promising alpha-glucosidase inhibitor, which therefore could be used as functional food to alleviate postprandial hyperglycemia and as a potential candidate for the development of an antidiabetic agent.	xanthohumol	32-34	sucrase-isomaltase	Homo sapiens	50-67
23994090-3	2013	In this study, we examined the ability of xanthohumol, a structurally simple prenylated chalcone, to suppress RANKL signaling during osteoclastogenesis in RAW264.7 cells.	xanthohumol	42-53	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	110-115
23978416-2	2013	Hyaluronan is exported from fibroblasts by the multidrug resistance associated protein 5 (MRP5) which is inhibited by the plant phenols curcumin or xanthohumol.	xanthohumol	148-159	ATP binding cassette subfamily C member 5	Homo sapiens	47-88
23978416-2	2013	Hyaluronan is exported from fibroblasts by the multidrug resistance associated protein 5 (MRP5) which is inhibited by the plant phenols curcumin or xanthohumol.	xanthohumol	148-159	ATP binding cassette subfamily C member 5	Homo sapiens	90-94
23994090-4	2013	Xanthohumol markedly inhibited RANKL-induced TRAP activity, multinucleated osteoclasts formation, and resorption-pit formation.	xanthohumol	0-11	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	31-36
23994090-5	2013	In experiments to elucidate its mechanism of action, xanthohumol was found to suppress RANKL-induced expression of TRAF6, GAB2, ERK, c-Src, PI3K, and Akt genes.	xanthohumol	53-64	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	87-92
23994090-5	2013	In experiments to elucidate its mechanism of action, xanthohumol was found to suppress RANKL-induced expression of TRAF6, GAB2, ERK, c-Src, PI3K, and Akt genes.	xanthohumol	53-64	TNF receptor-associated factor 6	Mus musculus	115-120
23994090-5	2013	In experiments to elucidate its mechanism of action, xanthohumol was found to suppress RANKL-induced expression of TRAF6, GAB2, ERK, c-Src, PI3K, and Akt genes.	xanthohumol	53-64	growth factor receptor bound protein 2-associated protein 2	Mus musculus	122-126
23994090-5	2013	In experiments to elucidate its mechanism of action, xanthohumol was found to suppress RANKL-induced expression of TRAF6, GAB2, ERK, c-Src, PI3K, and Akt genes.	xanthohumol	53-64	mitogen-activated protein kinase 1	Mus musculus	128-131
23994090-5	2013	In experiments to elucidate its mechanism of action, xanthohumol was found to suppress RANKL-induced expression of TRAF6, GAB2, ERK, c-Src, PI3K, and Akt genes.	xanthohumol	53-64	thymoma viral proto-oncogene 1	Mus musculus	150-153
23994090-6	2013	Moreover, RANKL-induced expressions of c-Fos and NFATc1, which are crucial transcription factors for osteoclastogenesis, were reduced by treatment with xanthohumol.	xanthohumol	152-163	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	10-15
23994090-6	2013	Moreover, RANKL-induced expressions of c-Fos and NFATc1, which are crucial transcription factors for osteoclastogenesis, were reduced by treatment with xanthohumol.	xanthohumol	152-163	FBJ osteosarcoma oncogene	Mus musculus	39-44
23994090-6	2013	Moreover, RANKL-induced expressions of c-Fos and NFATc1, which are crucial transcription factors for osteoclastogenesis, were reduced by treatment with xanthohumol.	xanthohumol	152-163	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	49-55
23994090-7	2013	Xanthohumol also inhibited RANKL-induced expression of bone-resorption related osteoclast-specific genes (carbonic anhydrase II, TCIRG, CLCN7, OSTM1, cathepsin K, and MMP-9).	xanthohumol	0-11	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	27-32
23994090-7	2013	Xanthohumol also inhibited RANKL-induced expression of bone-resorption related osteoclast-specific genes (carbonic anhydrase II, TCIRG, CLCN7, OSTM1, cathepsin K, and MMP-9).	xanthohumol	0-11	carbonic anhydrase 2	Mus musculus	106-127
23994090-7	2013	Xanthohumol also inhibited RANKL-induced expression of bone-resorption related osteoclast-specific genes (carbonic anhydrase II, TCIRG, CLCN7, OSTM1, cathepsin K, and MMP-9).	xanthohumol	0-11	chloride channel, voltage-sensitive 7	Mus musculus	136-141
23994090-7	2013	Xanthohumol also inhibited RANKL-induced expression of bone-resorption related osteoclast-specific genes (carbonic anhydrase II, TCIRG, CLCN7, OSTM1, cathepsin K, and MMP-9).	xanthohumol	0-11	osteopetrosis associated transmembrane protein 1	Mus musculus	143-148
23994090-7	2013	Xanthohumol also inhibited RANKL-induced expression of bone-resorption related osteoclast-specific genes (carbonic anhydrase II, TCIRG, CLCN7, OSTM1, cathepsin K, and MMP-9).	xanthohumol	0-11	cathepsin K	Mus musculus	150-161
23994090-7	2013	Xanthohumol also inhibited RANKL-induced expression of bone-resorption related osteoclast-specific genes (carbonic anhydrase II, TCIRG, CLCN7, OSTM1, cathepsin K, and MMP-9).	xanthohumol	0-11	matrix metallopeptidase 9	Mus musculus	167-172
23994090-8	2013	These data demonstrate that xanthohumol inhibits osteoclastogenesis by modulating RANKL signaling and may be useful for the prevention of bone-destructive diseases such as osteoporosis, arthritis and periodontitis.	xanthohumol	28-39	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	82-87
23650230-0	2013	Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE-deficient mice.	xanthohumol	0-11	apolipoprotein E	Mus musculus	105-109
23650230-3	2013	METHODS AND RESULTS: XN supplementation markedly reduced plasma cholesterol concentrations, decreased atherosclerotic lesion area, and attenuated plasma concentrations of the proinflammatory cytokine monocyte chemoattractant protein 1.	xanthohumol	21-23	chemokine (C-C motif) ligand 2	Mus musculus	200-234
23650230-5	2013	Concomitant induction of hepatic mRNA expression of carnitine palmitoyltransferase-1a in ApoE-/- mice-administered XN suggests increased fatty acid beta-oxidation.	xanthohumol	115-117	apolipoprotein E	Mus musculus	89-93
23650230-7	2013	CONCLUSION: The atheroprotective effects of XN might be attributed to combined beneficial effects on plasma cholesterol and monocyte chemoattractant protein 1 concentrations and hepatic lipid metabolism via activation of AMP-activated protein kinase.	xanthohumol	44-46	chemokine (C-C motif) ligand 2	Mus musculus	124-158
23669332-7	2013	XN significantly decreased malondialdehyde, potentiated superoxide dismutase and glutathione peroxidase, reduced Bax expression, promoted Bcl-xL and inhibited caspase 3 activity in liver tissues compared with the animals without XN intervention.	xanthohumol	0-2	BCL2 associated X, apoptosis regulator	Homo sapiens	113-116
23669332-7	2013	XN significantly decreased malondialdehyde, potentiated superoxide dismutase and glutathione peroxidase, reduced Bax expression, promoted Bcl-xL and inhibited caspase 3 activity in liver tissues compared with the animals without XN intervention.	xanthohumol	0-2	BCL2 like 1	Homo sapiens	138-144
23669332-7	2013	XN significantly decreased malondialdehyde, potentiated superoxide dismutase and glutathione peroxidase, reduced Bax expression, promoted Bcl-xL and inhibited caspase 3 activity in liver tissues compared with the animals without XN intervention.	xanthohumol	0-2	caspase 3	Homo sapiens	159-168
23503627-7	2013	Xanthohumol inhibited the activity of CYP, SELE and NF-kB and consequently, the formation of CCIDs at low micromolar concentrations.	xanthohumol	0-11	selectin E	Homo sapiens	43-47
23503627-8	2013	More specifically, xanthohumol affected ICAM-1 expression and adherence of MCF-7 cells to LECs, which is a prerequisite for CCID formation.	xanthohumol	19-30	intercellular adhesion molecule 1	Homo sapiens	40-46
23562496-9	2013	Xanthohumol and 2-hydroxychalcone induced apoptosis by Bcl-2 downregulation.	xanthohumol	0-11	BCL2 apoptosis regulator	Homo sapiens	55-60
23562496-10	2013	Importantly, 2-hydroxychalcone and xanthohumol exerted more potent inhibitory effects on the proliferation, MMP-9 expression and invasive phenotype of MDA-MB-231 than chalcone.	xanthohumol	35-46	matrix metallopeptidase 9	Homo sapiens	108-113
23085367-0	2013	Xanthohumol induces phase II enzymes via Nrf2 in human hepatocytes in vitro.	xanthohumol	0-11	NFE2 like bZIP transcription factor 2	Homo sapiens	41-45
23640998-1	2013	Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells.	xanthohumol	84-95	RELA proto-oncogene, NF-kB subunit	Homo sapiens	76-79
23246576-9	2013	Multi-drug resistance 1 (MDR1), epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3) expression levels in MCF-7/ADR cells were suppressed by xanthohumol treatment.	xanthohumol	191-202	ATP binding cassette subfamily B member 1	Homo sapiens	0-23
23246576-9	2013	Multi-drug resistance 1 (MDR1), epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3) expression levels in MCF-7/ADR cells were suppressed by xanthohumol treatment.	xanthohumol	191-202	ATP binding cassette subfamily B member 1	Homo sapiens	25-29
23246576-9	2013	Multi-drug resistance 1 (MDR1), epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3) expression levels in MCF-7/ADR cells were suppressed by xanthohumol treatment.	xanthohumol	191-202	epidermal growth factor receptor	Homo sapiens	32-64
23246576-9	2013	Multi-drug resistance 1 (MDR1), epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3) expression levels in MCF-7/ADR cells were suppressed by xanthohumol treatment.	xanthohumol	191-202	epidermal growth factor receptor	Homo sapiens	66-70
23246576-9	2013	Multi-drug resistance 1 (MDR1), epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3) expression levels in MCF-7/ADR cells were suppressed by xanthohumol treatment.	xanthohumol	191-202	signal transducer and activator of transcription 3	Homo sapiens	76-126
23246576-9	2013	Multi-drug resistance 1 (MDR1), epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3) expression levels in MCF-7/ADR cells were suppressed by xanthohumol treatment.	xanthohumol	191-202	signal transducer and activator of transcription 3	Homo sapiens	128-133
23085000-4	2013	Interactions of XN with DPPC were investigated as a function of temperature and its concentration by using X-ray diffraction and the ATR-FTIR spectroscopy techniques.	xanthohumol	16-18	ATR serine/threonine kinase	Homo sapiens	133-136
22634733-7	2013	However, at the same time point, pretreatment with xanthohumol almost completely blunted the I/R-induced AKT and NFkappaB activation and the expression of the proinflammatory genes IL-1alpha, IL-6, MCP-1 and ICAM-1, which are known to play a crucial role in the subacute phase of I/R-induced liver damage.	xanthohumol	51-62	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	113-121
22634733-7	2013	However, at the same time point, pretreatment with xanthohumol almost completely blunted the I/R-induced AKT and NFkappaB activation and the expression of the proinflammatory genes IL-1alpha, IL-6, MCP-1 and ICAM-1, which are known to play a crucial role in the subacute phase of I/R-induced liver damage.	xanthohumol	51-62	interleukin 1 alpha	Mus musculus	181-190
22634733-7	2013	However, at the same time point, pretreatment with xanthohumol almost completely blunted the I/R-induced AKT and NFkappaB activation and the expression of the proinflammatory genes IL-1alpha, IL-6, MCP-1 and ICAM-1, which are known to play a crucial role in the subacute phase of I/R-induced liver damage.	xanthohumol	51-62	interleukin 6	Mus musculus	192-196
22634733-7	2013	However, at the same time point, pretreatment with xanthohumol almost completely blunted the I/R-induced AKT and NFkappaB activation and the expression of the proinflammatory genes IL-1alpha, IL-6, MCP-1 and ICAM-1, which are known to play a crucial role in the subacute phase of I/R-induced liver damage.	xanthohumol	51-62	mast cell protease 1	Mus musculus	198-203
22634733-7	2013	However, at the same time point, pretreatment with xanthohumol almost completely blunted the I/R-induced AKT and NFkappaB activation and the expression of the proinflammatory genes IL-1alpha, IL-6, MCP-1 and ICAM-1, which are known to play a crucial role in the subacute phase of I/R-induced liver damage.	xanthohumol	51-62	intercellular adhesion molecule 1	Mus musculus	208-214
23085367-7	2013	The activation of Nrf2 pathway and subsequently phase II enzymes in concert with p53 induction in normal hepatocytes may account for the molecular mechanism of the chemopreventive activity of xanthohumol.	xanthohumol	192-203	tumor protein p53	Homo sapiens	81-84
23085367-1	2013	The aim of this study was to investigate whether xanthohumol may exert chemoprotective activity through the modulation of the nuclear factor erythroid-2-related factor 2 (Nrf2) pathway in immortalized normal THLE-2 hepatocytes and a hepatocellular carcinoma HepG2 cell line.	xanthohumol	49-60	NFE2 like bZIP transcription factor 2	Homo sapiens	126-169
23085367-1	2013	The aim of this study was to investigate whether xanthohumol may exert chemoprotective activity through the modulation of the nuclear factor erythroid-2-related factor 2 (Nrf2) pathway in immortalized normal THLE-2 hepatocytes and a hepatocellular carcinoma HepG2 cell line.	xanthohumol	49-60	NFE2 like bZIP transcription factor 2	Homo sapiens	171-175
23085367-4	2013	Xanthohumol increased the expression and led to the activation of Nrf2 in both cell lines.	xanthohumol	0-11	NFE2 like bZIP transcription factor 2	Homo sapiens	66-70
23085367-6	2013	Xanthohumol, beside the induction of GSTs and HO-1, significantly elevated NQO1 expression in concert with p53 level in normal hepatocytes.	xanthohumol	0-11	glutathione S-transferase pi 1	Homo sapiens	37-41
23085367-6	2013	Xanthohumol, beside the induction of GSTs and HO-1, significantly elevated NQO1 expression in concert with p53 level in normal hepatocytes.	xanthohumol	0-11	heme oxygenase 1	Homo sapiens	46-50
23085367-6	2013	Xanthohumol, beside the induction of GSTs and HO-1, significantly elevated NQO1 expression in concert with p53 level in normal hepatocytes.	xanthohumol	0-11	NAD(P)H quinone dehydrogenase 1	Homo sapiens	75-79
23085367-6	2013	Xanthohumol, beside the induction of GSTs and HO-1, significantly elevated NQO1 expression in concert with p53 level in normal hepatocytes.	xanthohumol	0-11	tumor protein p53	Homo sapiens	107-110
23085367-7	2013	The activation of Nrf2 pathway and subsequently phase II enzymes in concert with p53 induction in normal hepatocytes may account for the molecular mechanism of the chemopreventive activity of xanthohumol.	xanthohumol	192-203	NFE2 like bZIP transcription factor 2	Homo sapiens	18-22
22407755-3	2012	XN induced a higher rate of apoptosis in glioblastoma cells than in normal astrocytes, which was associated with activation of p53 and an elevated Bax/Bcl-2 ratio in glioblastoma cells, indicating an intrinsic caspase-dependent apoptotic pathway.	xanthohumol	0-2	tumor protein p53	Homo sapiens	127-130
23407460-6	2013	Importantly, apoptosis induced by XH was reduced in siRNA-ANXA1 transfected cells where western blot analysis shows a significant reduction of ANXA1 protein levels.	xanthohumol	34-36	annexin A1	Homo sapiens	58-63
23407460-6	2013	Importantly, apoptosis induced by XH was reduced in siRNA-ANXA1 transfected cells where western blot analysis shows a significant reduction of ANXA1 protein levels.	xanthohumol	34-36	annexin A1	Homo sapiens	143-148
22952060-0	2012	Xanthohumol impairs human prostate cancer cell growth and invasion and diminishes the incidence and progression of advanced tumors in TRAMP mice.	xanthohumol	0-11	TNF receptor superfamily member 25	Homo sapiens	134-139
23457589-6	2013	Treatment of NOD.Stat5b(Tg) mice with cancer chemopreventive agents Apigenin and Xanthohumol efficiently blocked lymphomagenesis through reduction of Stat5 phosphorylation and genes up-regulated in the NOD.Stat5b(Tg) mice.	xanthohumol	81-92	signal transducer and activator of transcription 5B	Mus musculus	17-23
23457589-6	2013	Treatment of NOD.Stat5b(Tg) mice with cancer chemopreventive agents Apigenin and Xanthohumol efficiently blocked lymphomagenesis through reduction of Stat5 phosphorylation and genes up-regulated in the NOD.Stat5b(Tg) mice.	xanthohumol	81-92	signal transducer and activator of transcription 5A	Mus musculus	17-22
23457589-6	2013	Treatment of NOD.Stat5b(Tg) mice with cancer chemopreventive agents Apigenin and Xanthohumol efficiently blocked lymphomagenesis through reduction of Stat5 phosphorylation and genes up-regulated in the NOD.Stat5b(Tg) mice.	xanthohumol	81-92	signal transducer and activator of transcription 5B	Mus musculus	17-27
23451393-1	2012	Hops (Humulus lupulus L.) are used in the brewing of beer, and hop extracts containing prenylated compounds, such as xanthohumol (XN) and 8-prenylnaringenin (8-PN), are under investigation as dietary supplements for cancer chemoprevention and the management of hot flashes in menopausal women.	xanthohumol	117-128	HOP homeobox	Homo sapiens	63-66
23451393-1	2012	Hops (Humulus lupulus L.) are used in the brewing of beer, and hop extracts containing prenylated compounds, such as xanthohumol (XN) and 8-prenylnaringenin (8-PN), are under investigation as dietary supplements for cancer chemoprevention and the management of hot flashes in menopausal women.	xanthohumol	130-132	HOP homeobox	Homo sapiens	63-66
23451393-2	2012	To facilitate clinical studies of hop safety and efficacy, a selective, sensitive, and fast ultra-high-pressure LC (UHPLC) tandem MS method was developed and validated for the simultaneous determination of the hop prenylflavonoids XN, isoxanthohumol (IX), 6-prenylnaringenin (6-PN), and 8-PN in human serum.	xanthohumol	231-233	HOP homeobox	Homo sapiens	210-213
22407755-3	2012	XN induced a higher rate of apoptosis in glioblastoma cells than in normal astrocytes, which was associated with activation of p53 and an elevated Bax/Bcl-2 ratio in glioblastoma cells, indicating an intrinsic caspase-dependent apoptotic pathway.	xanthohumol	0-2	BCL2 associated X, apoptosis regulator	Homo sapiens	147-150
22407755-3	2012	XN induced a higher rate of apoptosis in glioblastoma cells than in normal astrocytes, which was associated with activation of p53 and an elevated Bax/Bcl-2 ratio in glioblastoma cells, indicating an intrinsic caspase-dependent apoptotic pathway.	xanthohumol	0-2	BCL2 apoptosis regulator	Homo sapiens	151-156
22884764-1	2012	Xanthohumol (XN), a prenyl flavonoid present in beer, prevents the acute hepatic injury induced by carbon tetrachloride (CCl4) in rats.	xanthohumol	0-11	C-C motif chemokine ligand 4	Rattus norvegicus	121-125
22884764-1	2012	Xanthohumol (XN), a prenyl flavonoid present in beer, prevents the acute hepatic injury induced by carbon tetrachloride (CCl4) in rats.	xanthohumol	13-15	C-C motif chemokine ligand 4	Rattus norvegicus	121-125
22884764-2	2012	Pre-treatment of rats with XN significantly reduced the increased liver weight observed in CCl4-intoxicated rats, normalised the increased values of plasma lactate dehydrogenase, glutamate oxaloacetate transaminase and glutamate pyruvate transaminase activities and reduced the incidence of histopathological alterations produced by CCl4.	xanthohumol	27-29	C-C motif chemokine ligand 4	Rattus norvegicus	91-95
22884764-2	2012	Pre-treatment of rats with XN significantly reduced the increased liver weight observed in CCl4-intoxicated rats, normalised the increased values of plasma lactate dehydrogenase, glutamate oxaloacetate transaminase and glutamate pyruvate transaminase activities and reduced the incidence of histopathological alterations produced by CCl4.	xanthohumol	27-29	C-C motif chemokine ligand 4	Rattus norvegicus	333-337
22884764-6	2012	Our results suggest that the hepatoprotective effect of XN is based on its antioxidant properties as well as it being an efficient inhibitor of lipid peroxidation and a protector against the degradation of antioxidant enzymes induced by CCl4 intoxication.	xanthohumol	56-58	C-C motif chemokine ligand 4	Rattus norvegicus	237-241
22537682-4	2012	In vitro biological tests revealed the inhibitory activity of xanthohumol and isoxanthohumol on PDK1 and PKC protein kinases.	xanthohumol	62-73	pyruvate dehydrogenase kinase 1	Homo sapiens	96-100
22445931-0	2012	The AKT/NF-kappaB inhibitor xanthohumol is a potent anti-lymphocytic leukemia drug overcoming chemoresistance and cell infiltration.	xanthohumol	28-39	thymoma viral proto-oncogene 1	Mus musculus	4-7
22445931-0	2012	The AKT/NF-kappaB inhibitor xanthohumol is a potent anti-lymphocytic leukemia drug overcoming chemoresistance and cell infiltration.	xanthohumol	28-39	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	8-17
22611436-6	2012	Xanthohumol inhibited platelet activation accompanied by relative [Ca(2+)](i) mobilization, thromboxane A(2) formation, hydroxyl radical (OH( )) formation, and phospholipase C (PLC)gamma2, protein kinase C (PKC), mitogen-activated protein kinase (MAPK), and Akt phosphorylation.	xanthohumol	0-11	phospholipase C gamma 2	Homo sapiens	177-187
22295144-10	2012	These results suggest that the protective effects of xanthohumol in this toxic liver injury model involves direct mechanisms related to its ability to block both hepatic inflammation and the activation of hepatic stellate cells, presumable at least in part via decreasing NFkappaB activity.	xanthohumol	53-64	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	272-280
22611436-6	2012	Xanthohumol inhibited platelet activation accompanied by relative [Ca(2+)](i) mobilization, thromboxane A(2) formation, hydroxyl radical (OH( )) formation, and phospholipase C (PLC)gamma2, protein kinase C (PKC), mitogen-activated protein kinase (MAPK), and Akt phosphorylation.	xanthohumol	0-11	AKT serine/threonine kinase 1	Homo sapiens	258-261
22611436-9	2012	This study demonstrates for the first time that xanthohumol possesses potent antiplatelet activity which may initially inhibit the PI3-kinase/Akt, p38 MAPK, and PLCgamma2-PKC cascades, followed by inhibition of the thromboxane A(2) formation, thereby leading to inhibition of [Ca(2+)](i) and finally inhibition of platelet aggregation.	xanthohumol	48-59	AKT serine/threonine kinase 1	Homo sapiens	142-145
22611436-9	2012	This study demonstrates for the first time that xanthohumol possesses potent antiplatelet activity which may initially inhibit the PI3-kinase/Akt, p38 MAPK, and PLCgamma2-PKC cascades, followed by inhibition of the thromboxane A(2) formation, thereby leading to inhibition of [Ca(2+)](i) and finally inhibition of platelet aggregation.	xanthohumol	48-59	phospholipase C gamma 2	Homo sapiens	161-170
22111577-4	2011	Xanthohumol induced intracellular reactive oxygen species (ROS), an effect that was reduced by pretreatment with the antioxidant N-acetyl-L-cysteine (NAC).	xanthohumol	0-11	X-linked Kx blood group	Homo sapiens	150-153
23166663-0	2012	Xanthohumol prevents atherosclerosis by reducing arterial cholesterol content via CETP and apolipoprotein E in CETP-transgenic mice.	xanthohumol	0-11	apolipoprotein E	Mus musculus	91-107
23166663-7	2012	Furthermore, apolipoprotein E (apoE) was enriched in serum and the HDL-fraction in CETP-Tg mice after xanthohumol addition, suggesting that xanthohumol ameliorates reverse cholesterol transport via apoE-rich HDL resulting from CETP inhibition.	xanthohumol	102-113	apolipoprotein E	Mus musculus	13-29
23166663-7	2012	Furthermore, apolipoprotein E (apoE) was enriched in serum and the HDL-fraction in CETP-Tg mice after xanthohumol addition, suggesting that xanthohumol ameliorates reverse cholesterol transport via apoE-rich HDL resulting from CETP inhibition.	xanthohumol	102-113	apolipoprotein E	Mus musculus	31-35
23166663-7	2012	Furthermore, apolipoprotein E (apoE) was enriched in serum and the HDL-fraction in CETP-Tg mice after xanthohumol addition, suggesting that xanthohumol ameliorates reverse cholesterol transport via apoE-rich HDL resulting from CETP inhibition.	xanthohumol	140-151	apolipoprotein E	Mus musculus	13-29
23166663-7	2012	Furthermore, apolipoprotein E (apoE) was enriched in serum and the HDL-fraction in CETP-Tg mice after xanthohumol addition, suggesting that xanthohumol ameliorates reverse cholesterol transport via apoE-rich HDL resulting from CETP inhibition.	xanthohumol	140-151	apolipoprotein E	Mus musculus	31-35
23166663-7	2012	Furthermore, apolipoprotein E (apoE) was enriched in serum and the HDL-fraction in CETP-Tg mice after xanthohumol addition, suggesting that xanthohumol ameliorates reverse cholesterol transport via apoE-rich HDL resulting from CETP inhibition.	xanthohumol	140-151	apolipoprotein E	Mus musculus	198-202
23166663-8	2012	CONCLUSIONS: Our results suggest xanthohumol prevents cholesterol accumulation in atherogenic regions by HDL-C metabolism via CETP inhibition leading to apoE enhancement.	xanthohumol	33-44	apolipoprotein E	Mus musculus	153-157
22946339-0	2012	Anticancer agent xanthohumol inhibits IL-2 induced signaling pathways involved in T cell proliferation.	xanthohumol	17-28	interleukin 2	Mus musculus	38-42
22946339-2	2012	In the present study we show that XN inhibits the proliferation of mouse lymphoma cells and IL-2 induced proliferation and cell cycle progression in mouse splenic T cells.	xanthohumol	34-36	interleukin 2	Mus musculus	92-96
22946339-3	2012	The suppression of T cell proliferation by XN was due to the inhibition of IL-2 induced Janus kinase/signal transducers and activators of transcription (Jak/STAT) and extracellular signal-regulated kinase 1 and 2 (Erk1/2) signaling pathways.	xanthohumol	43-45	interleukin 2	Mus musculus	75-79
22946339-3	2012	The suppression of T cell proliferation by XN was due to the inhibition of IL-2 induced Janus kinase/signal transducers and activators of transcription (Jak/STAT) and extracellular signal-regulated kinase 1 and 2 (Erk1/2) signaling pathways.	xanthohumol	43-45	mitogen-activated protein kinase 3	Mus musculus	167-212
22946339-3	2012	The suppression of T cell proliferation by XN was due to the inhibition of IL-2 induced Janus kinase/signal transducers and activators of transcription (Jak/STAT) and extracellular signal-regulated kinase 1 and 2 (Erk1/2) signaling pathways.	xanthohumol	43-45	mitogen-activated protein kinase 3	Mus musculus	214-220
21565172-3	2011	In the present study, the effects of XN on osteoblast differentiation and function were determined by analyzing the activity of alkaline phosphatase (ALP), an osteoblast marker, and the regulation of RUNX2, a master gene of osteoblast differentiation, in a mesenchymal stem cell line.	xanthohumol	37-39	alkaline phosphatase, placental	Homo sapiens	128-148
21616523-0	2011	Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines.	xanthohumol	0-11	notch receptor 1	Homo sapiens	22-28
21616523-4	2011	We hypothesized that the Notch1 signaling pathway is targeted by xanthohumol leading to decreased ovarian cancer cell growth.	xanthohumol	65-76	notch receptor 1	Homo sapiens	25-31
21616523-10	2011	RESULTS: Significant growth inhibition and down-regulation of Notch1 transcription and protein expression were found following xanthohumol treatment.	xanthohumol	127-138	notch receptor 1	Homo sapiens	62-68
21616523-14	2011	CONCLUSION: Xanthohumol was a potent inhibitor of ovarian cancer cell growth, and our results suggest that xanthohumol may be influencing the Notch1 pathway.	xanthohumol	107-118	notch receptor 1	Homo sapiens	142-148
21565172-3	2011	In the present study, the effects of XN on osteoblast differentiation and function were determined by analyzing the activity of alkaline phosphatase (ALP), an osteoblast marker, and the regulation of RUNX2, a master gene of osteoblast differentiation, in a mesenchymal stem cell line.	xanthohumol	37-39	alkaline phosphatase, placental	Homo sapiens	150-153
21565172-3	2011	In the present study, the effects of XN on osteoblast differentiation and function were determined by analyzing the activity of alkaline phosphatase (ALP), an osteoblast marker, and the regulation of RUNX2, a master gene of osteoblast differentiation, in a mesenchymal stem cell line.	xanthohumol	37-39	RUNX family transcription factor 2	Homo sapiens	200-205
21670529-8	2011	Furthermore, injection of organic compounds such as xanthohumol, a DGAT inhibitor, into the Dga1p-immobilized chip surface induced significant SPR signals, probably due to interaction with DGAT.	xanthohumol	52-63	diacylglycerol O-acyltransferase	Saccharomyces cerevisiae S288C	92-97
21093515-5	2011	Xanthohumol significantly inhibited the excessive production of inflammatory mediators NO, IL-1beta, and TNF-alpha, and the activation of NF-kappaB signaling in LPS-induced stimulated BV2 cells.	xanthohumol	0-11	interleukin 1 beta	Mus musculus	91-99
21093515-5	2011	Xanthohumol significantly inhibited the excessive production of inflammatory mediators NO, IL-1beta, and TNF-alpha, and the activation of NF-kappaB signaling in LPS-induced stimulated BV2 cells.	xanthohumol	0-11	tumor necrosis factor	Mus musculus	105-114
21093515-6	2011	Xanthohumol up-regulated the transcription of NAD(P)H:quinone oxidoreductase 1 (NQO1) and heme oxygenase-1 (HO-1), and increased the level of the endogenous antioxidant GSH.	xanthohumol	0-11	NAD(P)H dehydrogenase, quinone 1	Mus musculus	46-78
21093515-6	2011	Xanthohumol up-regulated the transcription of NAD(P)H:quinone oxidoreductase 1 (NQO1) and heme oxygenase-1 (HO-1), and increased the level of the endogenous antioxidant GSH.	xanthohumol	0-11	NAD(P)H dehydrogenase, quinone 1	Mus musculus	80-84
21093515-6	2011	Xanthohumol up-regulated the transcription of NAD(P)H:quinone oxidoreductase 1 (NQO1) and heme oxygenase-1 (HO-1), and increased the level of the endogenous antioxidant GSH.	xanthohumol	0-11	heme oxygenase 1	Mus musculus	90-106
21093515-6	2011	Xanthohumol up-regulated the transcription of NAD(P)H:quinone oxidoreductase 1 (NQO1) and heme oxygenase-1 (HO-1), and increased the level of the endogenous antioxidant GSH.	xanthohumol	0-11	heme oxygenase 1	Mus musculus	108-112
21093515-7	2011	In addition, xanthohumol induced nuclear translocation of NRF2 and further activation of ARE promoter-related transcription.	xanthohumol	13-24	nuclear factor, erythroid derived 2, like 2	Mus musculus	58-62
21093515-8	2011	The anti-inflammatory response of xanthohumol was attenuated by transfection with NRF2 siRNA and in the presence of the HO-1 inhibitor, ZnPP, but not the NQO1 inhibitor, dicoumarol.	xanthohumol	34-45	nuclear factor, erythroid derived 2, like 2	Mus musculus	82-86
21093515-8	2011	The anti-inflammatory response of xanthohumol was attenuated by transfection with NRF2 siRNA and in the presence of the HO-1 inhibitor, ZnPP, but not the NQO1 inhibitor, dicoumarol.	xanthohumol	34-45	heme oxygenase 1	Mus musculus	120-124
20944105-6	2010	Induction of apoptosis by XN was associated with the inhibition of prosurvival Akt, NF-kappaB and mTOR signaling proteins and NF-kappaB-regulated anti-apoptotic Bcl-2 and survivin.	xanthohumol	26-28	AKT serine/threonine kinase 1	Homo sapiens	79-82
20309792-0	2010	Xanthohumol and related prenylated flavonoids inhibit inflammatory cytokine production in LPS-activated THP-1 monocytes: structure-activity relationships and in silico binding to myeloid differentiation protein-2 (MD-2).	xanthohumol	0-11	GLI family zinc finger 2	Homo sapiens	104-109
20309792-0	2010	Xanthohumol and related prenylated flavonoids inhibit inflammatory cytokine production in LPS-activated THP-1 monocytes: structure-activity relationships and in silico binding to myeloid differentiation protein-2 (MD-2).	xanthohumol	0-11	lymphocyte antigen 96	Homo sapiens	179-212
20309792-0	2010	Xanthohumol and related prenylated flavonoids inhibit inflammatory cytokine production in LPS-activated THP-1 monocytes: structure-activity relationships and in silico binding to myeloid differentiation protein-2 (MD-2).	xanthohumol	0-11	lymphocyte antigen 96	Homo sapiens	214-218
20944105-6	2010	Induction of apoptosis by XN was associated with the inhibition of prosurvival Akt, NF-kappaB and mTOR signaling proteins and NF-kappaB-regulated anti-apoptotic Bcl-2 and survivin.	xanthohumol	26-28	mechanistic target of rapamycin kinase	Homo sapiens	98-102
20944105-6	2010	Induction of apoptosis by XN was associated with the inhibition of prosurvival Akt, NF-kappaB and mTOR signaling proteins and NF-kappaB-regulated anti-apoptotic Bcl-2 and survivin.	xanthohumol	26-28	BCL2 apoptosis regulator	Homo sapiens	161-166
20461738-3	2010	Female rats treated orally with XN showed increased hepatic expression of T4-binding globulin and decreased transthyretin and albumin.	xanthohumol	32-34	serpin family A member 7	Rattus norvegicus	74-93
20335224-10	2010	Concomitantly, XN treatment caused a rapid breakdown of the mitochondrial membrane potential and the release of cytochrome c, leading to apoptosis induction.	xanthohumol	15-17	cytochrome c, somatic	Homo sapiens	112-124
20335224-11	2010	Pre- or coincubation with 2 mM NAC and 50 microM MnTMPyP at various steps increased XN-mediated IC(50) values for cytotoxicity in BPH-1 cells from 6.7 +/- 0.2 to 12.2 +/- 0.1 and 41.4 +/- 7.6 microM, and it confirmed XN-induced O(2)(-*) as an essential trigger for apoptosis induction.	xanthohumol	84-86	X-linked Kx blood group	Homo sapiens	31-34
20335224-11	2010	Pre- or coincubation with 2 mM NAC and 50 microM MnTMPyP at various steps increased XN-mediated IC(50) values for cytotoxicity in BPH-1 cells from 6.7 +/- 0.2 to 12.2 +/- 0.1 and 41.4 +/- 7.6 microM, and it confirmed XN-induced O(2)(-*) as an essential trigger for apoptosis induction.	xanthohumol	217-219	X-linked Kx blood group	Homo sapiens	31-34
20333722-7	2010	In conclusion, xanthohumol stimulated Asm leading to caspase activation and apoptosis of bone marrow-derived DCs.	xanthohumol	15-26	sphingomyelin phosphodiesterase 1, acid lysosomal	Mus musculus	38-41
20486208-1	2010	Hop-derived products may contain xanthohumol (XN), isoxanthohumol (IX), and the potent phytoestrogen 8-prenylnaringenin (8-PN).	xanthohumol	33-44	HOP homeobox	Homo sapiens	0-3
20486208-1	2010	Hop-derived products may contain xanthohumol (XN), isoxanthohumol (IX), and the potent phytoestrogen 8-prenylnaringenin (8-PN).	xanthohumol	46-48	HOP homeobox	Homo sapiens	0-3
20333722-6	2010	As a result, xanthohumol stimulated Asm, enhanced ceramide formation, activated caspases 8 and 3, triggered DNA fragmentation and led to cell membrane scrambling, all effects virtually absent in DCs from gene targeted mice lacking functional Asm or in wild-type cells treated with sphingomyelinase inhibitor amitriptyline.	xanthohumol	13-24	sphingomyelin phosphodiesterase 1, acid lysosomal	Mus musculus	36-39
20333722-6	2010	As a result, xanthohumol stimulated Asm, enhanced ceramide formation, activated caspases 8 and 3, triggered DNA fragmentation and led to cell membrane scrambling, all effects virtually absent in DCs from gene targeted mice lacking functional Asm or in wild-type cells treated with sphingomyelinase inhibitor amitriptyline.	xanthohumol	13-24	caspase 8	Mus musculus	80-96
20333722-6	2010	As a result, xanthohumol stimulated Asm, enhanced ceramide formation, activated caspases 8 and 3, triggered DNA fragmentation and led to cell membrane scrambling, all effects virtually absent in DCs from gene targeted mice lacking functional Asm or in wild-type cells treated with sphingomyelinase inhibitor amitriptyline.	xanthohumol	13-24	sphingomyelin phosphodiesterase 1, acid lysosomal	Mus musculus	242-245
20461738-5	2010	Northern blot analysis revealed diminished expression of liver sulfotransferase (Sult1a1) and uridine-diphosphate glucuronosyltransferase (Ugt1a1) after XN treatment.	xanthohumol	153-155	sulfotransferase family 1A member 1	Rattus norvegicus	81-88
20461738-5	2010	Northern blot analysis revealed diminished expression of liver sulfotransferase (Sult1a1) and uridine-diphosphate glucuronosyltransferase (Ugt1a1) after XN treatment.	xanthohumol	153-155	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	139-145
19748253-5	2010	The interaction between XN and IFN-alpha was significant (P<0.001).	xanthohumol	24-26	interferon alpha 1	Homo sapiens	31-40
20447364-0	2010	Direct inhibition of elastase and matrixmetalloproteinases and stimulation of biosynthesis of fibrillar collagens, elastin, and fibrillins by xanthohumol.	xanthohumol	142-153	elastin	Homo sapiens	115-122
20226902-0	2010	Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer.	xanthohumol	0-11	achaete-scute family bHLH transcription factor 1	Homo sapiens	61-89
20226902-0	2010	Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer.	xanthohumol	0-11	mitogen-activated protein kinase 3	Homo sapiens	144-150
20226902-4	2010	We thus hypothesized that xanthohumol would suppress growth by activating Raf-1 signaling, thus altering the malignant phenotype of MTC.	xanthohumol	26-37	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	74-79
20447364-5	2010	Xanthohumol significantly inhibited elastase and MMP-9 activities from its lowest concentration, and MMP-1 and MMP-2 at its higher concentrations, which implies a greater protective effect on elastin.	xanthohumol	0-11	matrix metallopeptidase 9	Homo sapiens	49-54
20447364-5	2010	Xanthohumol significantly inhibited elastase and MMP-9 activities from its lowest concentration, and MMP-1 and MMP-2 at its higher concentrations, which implies a greater protective effect on elastin.	xanthohumol	0-11	elastin	Homo sapiens	192-199
18952893-0	2009	Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells.	xanthohumol	84-95	NFKB inhibitor alpha	Homo sapiens	41-53
20043079-0	2010	Xanthohumol, a prenylated chalcone derived from hops, inhibits proliferation, migration and interleukin-8 expression of hepatocellular carcinoma cells.	xanthohumol	0-11	C-X-C motif chemokine ligand 8	Homo sapiens	92-105
20043079-2	2010	Here, we show that xanthohumol at a concentration of 25 microM induced apoptosis in two HCC cell lines (HepG2 and Huh7).	xanthohumol	19-30	MIR7-3 host gene	Homo sapiens	114-118
19757857-10	2009	Moreover, hepatic tissue damage as well as TNF-alpha levels increased in xanthohumol-pretreated liver tissue after ischemia/reperfusion.	xanthohumol	73-84	tumor necrosis factor	Rattus norvegicus	43-52
19735186-5	2009	Likewise, XN + GS caused a potentiated increase in caspase-3/7 activation, whereas neither of the compounds showed any effect individually.	xanthohumol	10-14	caspase 3	Homo sapiens	51-60
18952893-0	2009	Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells.	xanthohumol	84-95	RELA proto-oncogene, NF-kB subunit	Homo sapiens	76-79
18952893-5	2009	XN directly inhibited tumor necrosis factor-induced IkappaBalpha kinase (IKK) activation and a reducing agent abolished this inhibition, indicating the role of cysteine residue.	xanthohumol	0-2	NFKB inhibitor alpha	Homo sapiens	52-64
19555200-3	2009	The suppression of these cell-mediated immune responses by XN was at, least in part, due to the inhibition of nuclear factor kappa B (NF-kappaB) transcription factor through suppression of phosphorylation of IkappaBalpha, an inhibitor of NF-kappaB.	xanthohumol	59-61	nuclear factor kappa B subunit 1	Homo sapiens	110-132
19019318-0	2009	Increased IL-2 production in T cells by xanthohumol through enhanced NF-AT and AP-1 activity.	xanthohumol	40-51	jun proto-oncogene	Mus musculus	79-83
19555200-3	2009	The suppression of these cell-mediated immune responses by XN was at, least in part, due to the inhibition of nuclear factor kappa B (NF-kappaB) transcription factor through suppression of phosphorylation of IkappaBalpha, an inhibitor of NF-kappaB.	xanthohumol	59-61	nuclear factor kappa B subunit 1	Homo sapiens	134-143
19555200-3	2009	The suppression of these cell-mediated immune responses by XN was at, least in part, due to the inhibition of nuclear factor kappa B (NF-kappaB) transcription factor through suppression of phosphorylation of IkappaBalpha, an inhibitor of NF-kappaB.	xanthohumol	59-61	NFKB inhibitor alpha	Homo sapiens	208-220
19555200-3	2009	The suppression of these cell-mediated immune responses by XN was at, least in part, due to the inhibition of nuclear factor kappa B (NF-kappaB) transcription factor through suppression of phosphorylation of IkappaBalpha, an inhibitor of NF-kappaB.	xanthohumol	59-61	nuclear factor kappa B subunit 1	Homo sapiens	238-247
19132064-3	2009	Amidepsines and xanthohumol inhibited DGAT1 and DGAT2 with similar potency, whereas roselipins were found to inhibit DGAT2 selectively.	xanthohumol	16-27	diacylglycerol O-acyltransferase 1	Homo sapiens	38-43
19132064-3	2009	Amidepsines and xanthohumol inhibited DGAT1 and DGAT2 with similar potency, whereas roselipins were found to inhibit DGAT2 selectively.	xanthohumol	16-27	diacylglycerol O-acyltransferase 2	Homo sapiens	48-53
17126313-0	2007	Distinct modulation of alkaline phosphatase isoenzymes by 17beta-estradiol and xanthohumol in breast cancer MCF-7 cells.	xanthohumol	79-90	alkaline phosphatase, placental	Homo sapiens	23-43
18951251-11	2008	In conclusion, quercetin, naringenin, genistein, and xanthohumol reduced P-gp-mediated transport and increased the basolateral uptake rate of cimetidine.	xanthohumol	53-64	ATP binding cassette subfamily B member 1	Homo sapiens	73-77
18587269-4	2008	XH also inhibited alpha-melanocyte stimulating hormone- or forskolin-induced increases in melanogenesis, suggesting an action on the cAMP-dependent melanogenic pathway.	xanthohumol	0-2	pro-opiomelanocortin-alpha	Mus musculus	18-55
17531458-6	2008	On the other hand, [3H]FA uptake was significantly increased by chronic exposure to xanthohumol, quercetin or isoxanthohumol (0.1-10 microM), and this increase does not seem to result from changes in the level of RFC1 or FRalpha gene expression.	xanthohumol	84-95	replication factor C subunit 1	Homo sapiens	213-217
17531458-6	2008	On the other hand, [3H]FA uptake was significantly increased by chronic exposure to xanthohumol, quercetin or isoxanthohumol (0.1-10 microM), and this increase does not seem to result from changes in the level of RFC1 or FRalpha gene expression.	xanthohumol	84-95	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	221-228
17874298-10	2007	Moreover, the major adipocyte marker proteins such as PPARgamma, C/EBPalpha, and aP2 decreased after treatment with XN during the maturation period and that of DGAT1 decreased after treatment with XN and IXN.	xanthohumol	116-118	peroxisome proliferator activated receptor gamma	Mus musculus	54-63
17874298-10	2007	Moreover, the major adipocyte marker proteins such as PPARgamma, C/EBPalpha, and aP2 decreased after treatment with XN during the maturation period and that of DGAT1 decreased after treatment with XN and IXN.	xanthohumol	116-118	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	65-75
17874298-10	2007	Moreover, the major adipocyte marker proteins such as PPARgamma, C/EBPalpha, and aP2 decreased after treatment with XN during the maturation period and that of DGAT1 decreased after treatment with XN and IXN.	xanthohumol	116-118	transcription factor AP-2, alpha	Mus musculus	81-84
17874298-10	2007	Moreover, the major adipocyte marker proteins such as PPARgamma, C/EBPalpha, and aP2 decreased after treatment with XN during the maturation period and that of DGAT1 decreased after treatment with XN and IXN.	xanthohumol	197-199	diacylglycerol O-acyltransferase 1	Mus musculus	160-165
17579893-6	2007	Xanthohumol accumulation was temperature dependent and saturable with an apparent K(m )value of 26.5 +/- 4.66 muM and an apparent V(max) of 0.215 +/- 0.018 nmol/mg protein/min.	xanthohumol	0-11	latexin	Homo sapiens	110-113
18790751-2	2008	The hop flavonoid xanthohumol inhibits tumor growth by targeting the nuclear factor-kappaB and Akt pathways and angiogenesis.	xanthohumol	18-29	AKT serine/threonine kinase 1	Homo sapiens	95-98
18790751-4	2008	Xanthohumol inhibition of K562 cell viability was associated with induction of apoptosis, increased p21 and p53 expression, and decreased survivin levels.	xanthohumol	0-11	H3 histone pseudogene 16	Homo sapiens	100-103
18790751-4	2008	Xanthohumol inhibition of K562 cell viability was associated with induction of apoptosis, increased p21 and p53 expression, and decreased survivin levels.	xanthohumol	0-11	tumor protein p53	Homo sapiens	108-111
18790751-5	2008	We show that xanthohumol strongly inhibited Bcr-Abl expression at both mRNA and protein levels and show that xanthohumol caused elevation of intracellular reactive oxygen species and that the antioxidant N-acetylcysteine blunted xanthohumol-induced events.	xanthohumol	13-24	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	44-51
18328448-3	2008	This study investigated the inhibitory mechanism of xanthohumol (XN) against the inflammatory effectors (IL-1beta, TNF-alpha, and iNOS) in activated RAW264.7 macrophages by using different stimuli such as LPS, IFN-gamma, or LPS plus IFN-gamma.	xanthohumol	52-63	interleukin 1 beta	Mus musculus	105-113
18328448-3	2008	This study investigated the inhibitory mechanism of xanthohumol (XN) against the inflammatory effectors (IL-1beta, TNF-alpha, and iNOS) in activated RAW264.7 macrophages by using different stimuli such as LPS, IFN-gamma, or LPS plus IFN-gamma.	xanthohumol	52-63	tumor necrosis factor	Mus musculus	115-124
18328448-3	2008	This study investigated the inhibitory mechanism of xanthohumol (XN) against the inflammatory effectors (IL-1beta, TNF-alpha, and iNOS) in activated RAW264.7 macrophages by using different stimuli such as LPS, IFN-gamma, or LPS plus IFN-gamma.	xanthohumol	52-63	nitric oxide synthase 2, inducible	Mus musculus	130-134
18328448-3	2008	This study investigated the inhibitory mechanism of xanthohumol (XN) against the inflammatory effectors (IL-1beta, TNF-alpha, and iNOS) in activated RAW264.7 macrophages by using different stimuli such as LPS, IFN-gamma, or LPS plus IFN-gamma.	xanthohumol	52-63	toll-like receptor 4	Mus musculus	205-208
18328448-3	2008	This study investigated the inhibitory mechanism of xanthohumol (XN) against the inflammatory effectors (IL-1beta, TNF-alpha, and iNOS) in activated RAW264.7 macrophages by using different stimuli such as LPS, IFN-gamma, or LPS plus IFN-gamma.	xanthohumol	52-63	interferon gamma	Mus musculus	210-219
18328448-3	2008	This study investigated the inhibitory mechanism of xanthohumol (XN) against the inflammatory effectors (IL-1beta, TNF-alpha, and iNOS) in activated RAW264.7 macrophages by using different stimuli such as LPS, IFN-gamma, or LPS plus IFN-gamma.	xanthohumol	65-67	interleukin 1 beta	Mus musculus	105-113
18328448-3	2008	This study investigated the inhibitory mechanism of xanthohumol (XN) against the inflammatory effectors (IL-1beta, TNF-alpha, and iNOS) in activated RAW264.7 macrophages by using different stimuli such as LPS, IFN-gamma, or LPS plus IFN-gamma.	xanthohumol	65-67	tumor necrosis factor	Mus musculus	115-124
18328448-3	2008	This study investigated the inhibitory mechanism of xanthohumol (XN) against the inflammatory effectors (IL-1beta, TNF-alpha, and iNOS) in activated RAW264.7 macrophages by using different stimuli such as LPS, IFN-gamma, or LPS plus IFN-gamma.	xanthohumol	65-67	nitric oxide synthase 2, inducible	Mus musculus	130-134
17823911-0	2007	AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies.	xanthohumol	24-35	AKT serine/threonine kinase 1	Homo sapiens	0-3
17823911-0	2007	AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies.	xanthohumol	24-35	nuclear factor kappa B subunit 1	Homo sapiens	4-13
17823911-2	2007	METHODS: The antiangiogenic Akt/NF-kappaB inhibitor xanthohumol (XN) has in vitro activity against acute and chronic myelogenous leukemia cell lines (AML, CML) and fresh samples from patients were investigated.	xanthohumol	52-63	AKT serine/threonine kinase 1	Homo sapiens	28-31
17823911-2	2007	METHODS: The antiangiogenic Akt/NF-kappaB inhibitor xanthohumol (XN) has in vitro activity against acute and chronic myelogenous leukemia cell lines (AML, CML) and fresh samples from patients were investigated.	xanthohumol	52-63	nuclear factor kappa B subunit 1	Homo sapiens	32-41
17823911-2	2007	METHODS: The antiangiogenic Akt/NF-kappaB inhibitor xanthohumol (XN) has in vitro activity against acute and chronic myelogenous leukemia cell lines (AML, CML) and fresh samples from patients were investigated.	xanthohumol	65-67	AKT serine/threonine kinase 1	Homo sapiens	28-31
17823911-2	2007	METHODS: The antiangiogenic Akt/NF-kappaB inhibitor xanthohumol (XN) has in vitro activity against acute and chronic myelogenous leukemia cell lines (AML, CML) and fresh samples from patients were investigated.	xanthohumol	65-67	nuclear factor kappa B subunit 1	Homo sapiens	32-41
17126313-1	2007	OBJECTIVES: To examine the effect of 17beta-estradiol and xanthohumol in alkaline phosphatase (ALP) expression and activity in breast cancer MCF-7 cells.	xanthohumol	58-69	alkaline phosphatase, placental	Homo sapiens	73-93
17126313-1	2007	OBJECTIVES: To examine the effect of 17beta-estradiol and xanthohumol in alkaline phosphatase (ALP) expression and activity in breast cancer MCF-7 cells.	xanthohumol	58-69	alkaline phosphatase, placental	Homo sapiens	95-98
17126313-7	2007	RNA and protein expression of IALP, but not TNS-ALP, was also decreased by incubation with 10 microM xanthohumol (IC(50)) and was accompanied by a significant reduction in ALP activity.	xanthohumol	101-112	alkaline phosphatase, placental	Homo sapiens	31-34
15986430-7	2005	An aggregation assay demonstrated stimulation of aggregation of MCF-7/6 cells in the presence of 5 microM xanthohumol and this could be completely inhibited by an antibody against E-cadherin.	xanthohumol	106-117	cadherin 1	Homo sapiens	180-190
16507512-1	2006	The hypothesis tested was that specific flavonoids such as epicatechin gallate, epigallocatechin gallate, genistein, genistin, naringenin, naringin, quercetin and xanthohumol will modulate cellular uptake and permeability (P(e)) of multidrug-resistant substrates, cyclosporin A (CSA) and digoxin, across Caco-2 and MDCKII-MDR1 cell transport models.	xanthohumol	163-174	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	279-282
16507512-1	2006	The hypothesis tested was that specific flavonoids such as epicatechin gallate, epigallocatechin gallate, genistein, genistin, naringenin, naringin, quercetin and xanthohumol will modulate cellular uptake and permeability (P(e)) of multidrug-resistant substrates, cyclosporin A (CSA) and digoxin, across Caco-2 and MDCKII-MDR1 cell transport models.	xanthohumol	163-174	ATP binding cassette subfamily B member 1	Homo sapiens	322-326
16507512-3	2006	Aglycone flavonoids reduced the P(e) of CSA to a greater extent than glycosylated flavonoids with 30 microM xanthohumol producing the greatest effect (7.2 x 10(-6) to 6.6 x 10(-7) and 17.9 x 10(-6) to 4.02 x 10(-6) cm s(-1) in Caco-2 and MDCKII-MDR1 cells, respectively); while no measurable effects were seen with digoxin.	xanthohumol	108-119	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	40-43
16507512-3	2006	Aglycone flavonoids reduced the P(e) of CSA to a greater extent than glycosylated flavonoids with 30 microM xanthohumol producing the greatest effect (7.2 x 10(-6) to 6.6 x 10(-7) and 17.9 x 10(-6) to 4.02 x 10(-6) cm s(-1) in Caco-2 and MDCKII-MDR1 cells, respectively); while no measurable effects were seen with digoxin.	xanthohumol	108-119	ATP binding cassette subfamily B member 1	Homo sapiens	245-249
16507512-4	2006	Xanthohumol significantly demonstrated (1) saturable efflux, (2) increased uptake of (3)H-digoxin and (3) decreased uptake of (3)H-CSA in the Caco-2 cells.	xanthohumol	0-11	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	131-134
16889681-6	2006	Moreover, chronic (48 h) exposure of cells to caffeine (1 microM) stimulated and chronic exposure to xanthohumol and iso-xanthohumol (1 and 0.1 microM, respectively) inhibited (3)H-thiamine uptake, these effects being not mediated through modulation of the expression levels of either hThTr-1 or hSERT mRNA.	xanthohumol	101-112	solute carrier family 19 member 2	Homo sapiens	285-292
16889681-6	2006	Moreover, chronic (48 h) exposure of cells to caffeine (1 microM) stimulated and chronic exposure to xanthohumol and iso-xanthohumol (1 and 0.1 microM, respectively) inhibited (3)H-thiamine uptake, these effects being not mediated through modulation of the expression levels of either hThTr-1 or hSERT mRNA.	xanthohumol	101-112	solute carrier family 6 member 4	Homo sapiens	296-301
15986430-8	2005	Xanthohumol upregulates the function of the E-cadherin/catenin complex and inhibits invasion in vitro, indicating a possible role as an antiinvasive agent in vivo as well.	xanthohumol	0-11	cadherin 1	Homo sapiens	44-54
16092069-0	2005	In vitro phase II metabolism of xanthohumol by human UDP-glucuronosyltransferases and sulfotransferases.	xanthohumol	32-43	beta-1,3-glucuronyltransferase 2	Homo sapiens	53-81
16140264-1	2005	We have examined the modulating action of xanthohumol (XN) on the farnesoid X receptor (FXR) in vitro and in vivo.	xanthohumol	42-53	nuclear receptor subfamily 1, group H, member 4	Mus musculus	88-91
16140264-1	2005	We have examined the modulating action of xanthohumol (XN) on the farnesoid X receptor (FXR) in vitro and in vivo.	xanthohumol	55-57	nuclear receptor subfamily 1, group H, member 4	Mus musculus	88-91
16140264-2	2005	In the transient transfection assay, XN dose-dependently increased the BSEP promoter-driven luciferase activity.	xanthohumol	37-39	ATP-binding cassette, sub-family B (MDR/TAP), member 11	Mus musculus	71-75
16140264-6	2005	However, the expression of cholesterol 7-hydroxylase (CYP7A1) was significantly induced in the liver of XN-fed mice.	xanthohumol	104-106	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	54-60
15995977-9	2005	Expression of anti-apoptotic Bcl-2 was down regulated when the cells were treated with XN for 48--72 h. We conclude that induction of apoptosis by downregulation of Bcl-2 and activation of the caspase cascade may contribute to the chemopreventive or therapeutic potential of XN.	xanthohumol	87-89	BCL2 apoptosis regulator	Homo sapiens	29-34
15995977-9	2005	Expression of anti-apoptotic Bcl-2 was down regulated when the cells were treated with XN for 48--72 h. We conclude that induction of apoptosis by downregulation of Bcl-2 and activation of the caspase cascade may contribute to the chemopreventive or therapeutic potential of XN.	xanthohumol	87-89	BCL2 apoptosis regulator	Homo sapiens	165-170
15995977-9	2005	Expression of anti-apoptotic Bcl-2 was down regulated when the cells were treated with XN for 48--72 h. We conclude that induction of apoptosis by downregulation of Bcl-2 and activation of the caspase cascade may contribute to the chemopreventive or therapeutic potential of XN.	xanthohumol	87-89	caspase 8	Homo sapiens	193-200
15995977-9	2005	Expression of anti-apoptotic Bcl-2 was down regulated when the cells were treated with XN for 48--72 h. We conclude that induction of apoptosis by downregulation of Bcl-2 and activation of the caspase cascade may contribute to the chemopreventive or therapeutic potential of XN.	xanthohumol	275-277	BCL2 apoptosis regulator	Homo sapiens	29-34
15995977-9	2005	Expression of anti-apoptotic Bcl-2 was down regulated when the cells were treated with XN for 48--72 h. We conclude that induction of apoptosis by downregulation of Bcl-2 and activation of the caspase cascade may contribute to the chemopreventive or therapeutic potential of XN.	xanthohumol	275-277	caspase 8	Homo sapiens	193-200
16092068-8	2005	In contrast to many other plant-derived phenolic secondary metabolites such as (iso-)flavonoids, which inhibit I(-) uptake, XN might be an interesting candidate for more efficient radioiodide therapy of thyroid and perhaps other cancer expressing NIS such as breast cancer.	xanthohumol	124-126	solute carrier family 5 member 5	Rattus norvegicus	247-250
16092069-3	2005	Therefore, we studied the in vitro phase II metabolism of XN using nine human recombinant UDP-glucuronosyltransferases (UGT) and five sulfotransferases (SULT).	xanthohumol	58-60	beta-1,3-glucuronyltransferase 2	Homo sapiens	120-123
16092069-4	2005	The identification of the metabolites formed was elucidated using HPLC with diode array detection as well as HPLC/API-ES MS. XN was efficiently glucuronidated by UGT 1 A 8, 1 A 9, and 1 A 10; further important UGTs were UGT 1 A 1, 1 A 7, and 2 B 7.	xanthohumol	125-127	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	162-178
16092069-4	2005	The identification of the metabolites formed was elucidated using HPLC with diode array detection as well as HPLC/API-ES MS. XN was efficiently glucuronidated by UGT 1 A 8, 1 A 9, and 1 A 10; further important UGTs were UGT 1 A 1, 1 A 7, and 2 B 7.	xanthohumol	125-127	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	220-229
10752639-7	2000	At 10 microM, the prenylated chalcone, xanthohumol (XN), almost completely inhibited the 7-ethoxyresorufin O-deethylase (EROD) activity of CYP1A1.	xanthohumol	39-50	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	139-145
15173394-0	2004	The chalcone xanthohumol inhibits triglyceride and apolipoprotein B secretion in HepG2 cells.	xanthohumol	13-24	apolipoprotein B	Homo sapiens	51-67
15173394-1	2004	The present study examined the role of xanthohumol (XN), a plant chalcone, on apolipoprotein B (apoB) and triglyceride (TG) synthesis and secretion, using HepG2 cells as the model system.	xanthohumol	39-50	apolipoprotein B	Homo sapiens	78-94
15173394-1	2004	The present study examined the role of xanthohumol (XN), a plant chalcone, on apolipoprotein B (apoB) and triglyceride (TG) synthesis and secretion, using HepG2 cells as the model system.	xanthohumol	52-54	apolipoprotein B	Homo sapiens	78-94
15173394-5	2004	XN inhibited the synthesis of TG in the microsomal membrane and the transfer of this newly synthesized TG to the microsomal lumen (decreases of 26 and 64%, respectively, under lipid-rich conditions), indicating that TG availability is a determining factor in the regulation of apoB secretion under the experimental conditions.	xanthohumol	0-2	apolipoprotein B	Homo sapiens	277-281
15173394-10	2004	In summary, the data suggest that xanthohumol is a potent inhibitor of apoB secretion.	xanthohumol	34-45	apolipoprotein B	Homo sapiens	71-75
15003419-1	2004	Xanthohumol (1), isolated from hop, was fed to rats in a dose of 1000 mg kg(-1) body weight.	xanthohumol	0-11	stress-induced phosphoprotein 1	Rattus norvegicus	31-34
11038156-4	2000	Inhibition studies showed that the prenylchalcone xanthohumol and the prenylflavanones 8-prenylnaringenin and isoxanthohumol strongly inhibited the mutagenic activation of IQ mediated by cDNA-expressed human CYP1A2 in the Ames Salmonella assay.	xanthohumol	50-61	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	208-214
11038156-7	2000	Thus, xanthohumol, isoxanthohumol, and prenylflavanones 8-prenylnaringenin are potent inhibitors of the metabolic activation of IQ and may have the potential to act as chemopreventive agents against cancer induced by heterocyclic amines activated by CYP1A2.	xanthohumol	6-17	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	250-256
15790308-4	2005	Molecules, such as xanthohumol and sophoraflavanone G, while being very structurally simple, show numerous pharmacological applications and are ideal candidates for SAR aimed to the discovery of new drugs.	xanthohumol	19-30	sarcosine dehydrogenase	Homo sapiens	165-168
14565769-4	2003	The two main oxidation products obtained by SIN-1 and peroxynitrite treatment of xanthohumol (XN), the principal prenylflavonoid of hops, were the aurone, auroxanthohumol (AUXN), and an endoperoxy derivative of XN, named endoperoxyxanthohumol (EPOX).	xanthohumol	94-96	MAPK associated protein 1	Homo sapiens	44-49
14565769-4	2003	The two main oxidation products obtained by SIN-1 and peroxynitrite treatment of xanthohumol (XN), the principal prenylflavonoid of hops, were the aurone, auroxanthohumol (AUXN), and an endoperoxy derivative of XN, named endoperoxyxanthohumol (EPOX).	xanthohumol	174-176	MAPK associated protein 1	Homo sapiens	44-49
10752639-7	2000	At 10 microM, the prenylated chalcone, xanthohumol (XN), almost completely inhibited the 7-ethoxyresorufin O-deethylase (EROD) activity of CYP1A1.	xanthohumol	52-54	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	139-145
10752639-10	2000	At 10 microM, XN completely eliminated CYP1B1 EROD activity, whereas the other hop flavonoids showed varying degrees of inhibitory action ranging from 99.3 to 1.8%.	xanthohumol	14-16	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	39-45
33820826-7	2021	Last, treatment with the PHB2 ligand xanthohumol blocks AURKA-induced mitophagy by destabilising the tripartite complex and restores normal ATP production levels.	xanthohumol	37-48	prohibitin 2	Homo sapiens	25-29
9366096-5	1997	Xanthohumol and xanthohumol B inhibited DGAT activity with IC50 values of 50.3 and 194 microM in rat liver microsomes, respectively.	xanthohumol	0-11	diacylglycerol O-acyltransferase 1	Rattus norvegicus	40-44
33820826-7	2021	Last, treatment with the PHB2 ligand xanthohumol blocks AURKA-induced mitophagy by destabilising the tripartite complex and restores normal ATP production levels.	xanthohumol	37-48	aurora kinase A	Homo sapiens	56-61
34944062-6	2021	Combination of xanthohumol and phenethyl isothiocyanate was more effective than single compounds at decreasing the canonical and non-canonical activation of Nrf2 in PSN-1 cancer cells.	xanthohumol	15-26	nuclear factor, erythroid derived 2, like 2	Mus musculus	157-161
34578877-0	2021	Comparison of the Impact of Xanthohumol and Phenethyl Isothiocyanate and Their Combination on Nrf2 and NF-kappaB Pathways in HepG2 Cells In Vitro and Tumor Burden In Vivo.	xanthohumol	28-39	NFE2 like bZIP transcription factor 2	Homo sapiens	94-98
34804373-6	2021	The involvement of NOX in XN-induced ROS generation was further evaluated: immunofluorescence assay indicated subunits assembled in the membrane, and gp91phox knockdown with siRNA decreased XN-induced ROS.	xanthohumol	26-28	cytochrome b-245 beta chain	Homo sapiens	150-158
34804373-6	2021	The involvement of NOX in XN-induced ROS generation was further evaluated: immunofluorescence assay indicated subunits assembled in the membrane, and gp91phox knockdown with siRNA decreased XN-induced ROS.	xanthohumol	190-192	cytochrome b-245 beta chain	Homo sapiens	150-158
34616299-0	2021	Xanthohumol Inhibited Mechanical Stimulation-Induced Articular ECM Degradation by Mediating lncRNA GAS5/miR-27a Axis.	xanthohumol	0-11	growth arrest specific 5	Homo sapiens	99-103
34616299-0	2021	Xanthohumol Inhibited Mechanical Stimulation-Induced Articular ECM Degradation by Mediating lncRNA GAS5/miR-27a Axis.	xanthohumol	0-11	microRNA 27a	Homo sapiens	104-111
34616299-10	2021	Collectively, XH exhibited protective effects against mechanical stimulation-induced ECM degradation by mediating the GAS5/miR-27a signaling pathway in OA chondrocytes.	xanthohumol	14-16	growth arrest specific 5	Homo sapiens	118-122
34616299-10	2021	Collectively, XH exhibited protective effects against mechanical stimulation-induced ECM degradation by mediating the GAS5/miR-27a signaling pathway in OA chondrocytes.	xanthohumol	14-16	microRNA 27a	Homo sapiens	123-130
34551612-0	2021	Xanthohumol alleviated T2DM-induced liver steatosis and fibrosis by mediating the NRF2/RAGE/NF-kappaB signaling pathway.	xanthohumol	0-11	NFE2 like bZIP transcription factor 2	Rattus norvegicus	82-86
34551612-0	2021	Xanthohumol alleviated T2DM-induced liver steatosis and fibrosis by mediating the NRF2/RAGE/NF-kappaB signaling pathway.	xanthohumol	0-11	advanced glycosylation end product-specific receptor	Rattus norvegicus	87-91
34551612-9	2021	XH attenuated the expression of RAGE and NF-kappaB signaling.	xanthohumol	0-2	advanced glycosylation end product-specific receptor	Rattus norvegicus	32-36
34551612-10	2021	XH significantly alleviated inflammation and oxidation by upregulating NRF2 expression.	xanthohumol	0-2	NFE2 like bZIP transcription factor 2	Rattus norvegicus	71-75
34398408-0	2021	Xanthohumol Attenuates Lipopolysaccharide-Induced Depressive Like Behavior in Mice: Involvement of NF-kappaB/Nrf2 Signaling Pathways.	xanthohumol	0-11	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	99-108
34398408-0	2021	Xanthohumol Attenuates Lipopolysaccharide-Induced Depressive Like Behavior in Mice: Involvement of NF-kappaB/Nrf2 Signaling Pathways.	xanthohumol	0-11	nuclear factor, erythroid derived 2, like 2	Mus musculus	109-113
34830015-5	2021	Here, we report that Xanthohumol, a small molecule in clinical trials from hops (Humulus lupulus), was a potent pan-inhibitor for various coronaviruses by targeting Mpro, for example, betacoronavirus SARS-CoV-2 (IC50 value of 1.53 muM), and alphacoronavirus PEDV (IC50 value of 7.51 muM).	xanthohumol	21-32	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	165-169
34830015-6	2021	Xanthohumol inhibited Mpro activities in the enzymatical assays, while pretreatment with Xanthohumol restricted the SARS-CoV-2 and PEDV replication in Vero-E6 cells.	xanthohumol	0-11	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	22-26
34702802-6	2021	Importantly, a cheap and orally available DGAT inhibitor, xanthohumol, was found to suppress SARS-CoV-2 replication and the associated pulmonary inflammation in a hamster model.	xanthohumol	58-69	diacylglycerol O-acyltransferase 1	Homo sapiens	42-46
34578877-0	2021	Comparison of the Impact of Xanthohumol and Phenethyl Isothiocyanate and Their Combination on Nrf2 and NF-kappaB Pathways in HepG2 Cells In Vitro and Tumor Burden In Vivo.	xanthohumol	28-39	nuclear factor kappa B subunit 1	Homo sapiens	103-112
34204745-11	2021	Furthermore, the XN-treatment counteracted the PMA-induced EMT of the A549 cells by the upregulation of E-cadherin and alpha-E-catenin and the downregulation of N-cadherin, vimentin, and Snail-1 expression.	xanthohumol	17-19	cadherin 1	Homo sapiens	104-114
34575438-4	2021	In this study, xanthohumol prevented tert-butyl hydroperoxide-induced loss of cell viability in human corneal epithelial (HCE-T) cells in a dose-dependent manner and resulted in a significant increase in expression of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2), the master regulator of phase II endogenous antioxidant enzymes.	xanthohumol	15-26	NFE2 like bZIP transcription factor 2	Homo sapiens	243-286
34575438-4	2021	In this study, xanthohumol prevented tert-butyl hydroperoxide-induced loss of cell viability in human corneal epithelial (HCE-T) cells in a dose-dependent manner and resulted in a significant increase in expression of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2), the master regulator of phase II endogenous antioxidant enzymes.	xanthohumol	15-26	NFE2 like bZIP transcription factor 2	Homo sapiens	288-292
34128467-0	2021	Tetrahydroxanthohumol, a xanthohumol derivative, attenuates high-fat diet-induced hepatic steatosis by antagonizing PPARgamma.	xanthohumol	25-36	peroxisome proliferator activated receptor gamma	Mus musculus	116-125
34128467-6	2021	A peroxisome proliferator activated receptor gamma (PPARgamma) competitive binding assay showed that XN and TXN bind to PPARgamma with an IC50 similar to pioglitazone and 8-10 times stronger than oleate.	xanthohumol	101-103	peroxisome proliferator activated receptor gamma	Mus musculus	2-50
34128467-6	2021	A peroxisome proliferator activated receptor gamma (PPARgamma) competitive binding assay showed that XN and TXN bind to PPARgamma with an IC50 similar to pioglitazone and 8-10 times stronger than oleate.	xanthohumol	101-103	peroxisome proliferator activated receptor gamma	Mus musculus	52-61
34128467-6	2021	A peroxisome proliferator activated receptor gamma (PPARgamma) competitive binding assay showed that XN and TXN bind to PPARgamma with an IC50 similar to pioglitazone and 8-10 times stronger than oleate.	xanthohumol	101-103	peroxisome proliferator activated receptor gamma	Mus musculus	120-129
34128467-7	2021	Molecular docking simulations demonstrated that XN and TXN bind in the PPARgamma ligand-binding domain pocket.	xanthohumol	48-50	peroxisome proliferator activated receptor gamma	Mus musculus	71-80
34204745-11	2021	Furthermore, the XN-treatment counteracted the PMA-induced EMT of the A549 cells by the upregulation of E-cadherin and alpha-E-catenin and the downregulation of N-cadherin, vimentin, and Snail-1 expression.	xanthohumol	17-19	catenin alpha 1	Homo sapiens	119-134
34204745-11	2021	Furthermore, the XN-treatment counteracted the PMA-induced EMT of the A549 cells by the upregulation of E-cadherin and alpha-E-catenin and the downregulation of N-cadherin, vimentin, and Snail-1 expression.	xanthohumol	17-19	cadherin 2	Homo sapiens	161-171
34204745-11	2021	Furthermore, the XN-treatment counteracted the PMA-induced EMT of the A549 cells by the upregulation of E-cadherin and alpha-E-catenin and the downregulation of N-cadherin, vimentin, and Snail-1 expression.	xanthohumol	17-19	vimentin	Homo sapiens	173-181
34204745-11	2021	Furthermore, the XN-treatment counteracted the PMA-induced EMT of the A549 cells by the upregulation of E-cadherin and alpha-E-catenin and the downregulation of N-cadherin, vimentin, and Snail-1 expression.	xanthohumol	17-19	snail family transcriptional repressor 1	Homo sapiens	187-194
35106609-0	2022	Hops extract and xanthohumol ameliorate bone loss induced by iron overload via activating Akt/GSK3beta/Nrf2 pathway.	xanthohumol	17-28	thymoma viral proto-oncogene 1	Mus musculus	90-93
34120541-5	2022	The mixture of XAN and PEITC was found to be the most potent modulator of the Nrf2 pathway.	xanthohumol	15-18	NFE2 like bZIP transcription factor 2	Homo sapiens	78-82
35229981-0	2022	Xanthohumol targets the JNK1/2 signaling pathway in apoptosis of human nasopharyngeal carcinoma cells.	xanthohumol	0-11	mitogen-activated protein kinase 8	Homo sapiens	24-30
35594207-5	2022	Xanthohumol is as an uncompetitive inhibitor of Na+-dependent 3H-GLN uptake and inhibits GPNA (L-gamma-glutamyl-p-nitroanilide)-sensitive, both ASCT2 (alanine, serine, cysteine transporter 2)-mediated and non-ASCT2-mediated 3H-GLN uptake.	xanthohumol	0-11	solute carrier family 1 member 5	Homo sapiens	144-149
35594207-5	2022	Xanthohumol is as an uncompetitive inhibitor of Na+-dependent 3H-GLN uptake and inhibits GPNA (L-gamma-glutamyl-p-nitroanilide)-sensitive, both ASCT2 (alanine, serine, cysteine transporter 2)-mediated and non-ASCT2-mediated 3H-GLN uptake.	xanthohumol	0-11	solute carrier family 1 member 5	Homo sapiens	209-214
35594207-7	2022	The cytotoxic effect of xanthohumol, but not its anti-proliferative effect, is GPNA-sensitive and related to ASCT2 inhibition.	xanthohumol	24-35	solute carrier family 1 member 5	Homo sapiens	109-114
35106609-0	2022	Hops extract and xanthohumol ameliorate bone loss induced by iron overload via activating Akt/GSK3beta/Nrf2 pathway.	xanthohumol	17-28	glycogen synthase kinase 3 alpha	Mus musculus	94-102
35106609-0	2022	Hops extract and xanthohumol ameliorate bone loss induced by iron overload via activating Akt/GSK3beta/Nrf2 pathway.	xanthohumol	17-28	nuclear factor, erythroid derived 2, like 2	Mus musculus	103-107
33925918-14	2021	CONCLUSION: These data supported that XN could induce AIF pathway apoptosis of the rat glioma C6 cells by affecting the mitochondria.	xanthohumol	38-40	apoptosis inducing factor, mitochondria associated 1	Rattus norvegicus	54-57
35563976-0	2022	Inverse Molecular Docking Elucidating the Anticarcinogenic Potential of the Hop Natural Product Xanthohumol and Its Metabolites.	xanthohumol	96-107	HOP homeobox	Homo sapiens	76-79
35563976-9	2022	More than half of the human protein targets of xanthohumol with the highest docking scores have already been connected with the anticarcinogenic function, and four of them (including two important representatives of the matrix metalloproteinase family, MMP-2 and MMP-9) also have a known experimental correlation with xanthohumol.	xanthohumol	47-58	matrix metallopeptidase 2	Homo sapiens	253-258
35563976-9	2022	More than half of the human protein targets of xanthohumol with the highest docking scores have already been connected with the anticarcinogenic function, and four of them (including two important representatives of the matrix metalloproteinase family, MMP-2 and MMP-9) also have a known experimental correlation with xanthohumol.	xanthohumol	47-58	matrix metallopeptidase 9	Homo sapiens	263-268
35563976-10	2022	Another important protein target is acyl-protein thioesterase 2, to which xanthohumol, isoxanthohumol, and 6-prenylnaringenin were successfully docked with the lowest docking scores.	xanthohumol	74-85	lysophospholipase 2	Homo sapiens	36-63
34999176-0	2022	Dietary prenylated flavonoid xanthohumol alleviates oxidative damage and accelerates diabetic wound healing via Nrf2 activation.	xanthohumol	29-40	NFE2 like bZIP transcription factor 2	Homo sapiens	112-116
33635505-1	2021	Naturally occurring phytochemicals of different origin and structure, arctigenin, bergenin, usnic acid and xanthohumol, were shown to affect Nrf2 pathway in the context of various diseases, but their effect on this pathway in cancer cells was not extensively investigated.	xanthohumol	107-118	NFE2 like bZIP transcription factor 2	Homo sapiens	141-145
34017261-0	2021	Xanthohumol Attenuated Inflammation and ECM Degradation by Mediating HO-1/C/EBPbeta Pathway in Osteoarthritis Chondrocytes.	xanthohumol	0-11	heme oxygenase 1	Homo sapiens	69-73
34017261-0	2021	Xanthohumol Attenuated Inflammation and ECM Degradation by Mediating HO-1/C/EBPbeta Pathway in Osteoarthritis Chondrocytes.	xanthohumol	0-11	CCAAT enhancer binding protein alpha	Homo sapiens	74-83
34017261-7	2021	In this article, we found that XH significantly inhibited inflammatory responses, attenuated catabolic enzymes expression, and ameliorated ECM degradation, as showed by decreased production of NO, PGE2, TNFalpha, and IL-6, decreased expression of MMP-3/-13 and ADAMTS-4/-5, and increased expression of collagen-II and aggrecan.	xanthohumol	31-33	tumor necrosis factor	Homo sapiens	203-211
34017261-7	2021	In this article, we found that XH significantly inhibited inflammatory responses, attenuated catabolic enzymes expression, and ameliorated ECM degradation, as showed by decreased production of NO, PGE2, TNFalpha, and IL-6, decreased expression of MMP-3/-13 and ADAMTS-4/-5, and increased expression of collagen-II and aggrecan.	xanthohumol	31-33	interleukin 6	Homo sapiens	217-221
34017261-7	2021	In this article, we found that XH significantly inhibited inflammatory responses, attenuated catabolic enzymes expression, and ameliorated ECM degradation, as showed by decreased production of NO, PGE2, TNFalpha, and IL-6, decreased expression of MMP-3/-13 and ADAMTS-4/-5, and increased expression of collagen-II and aggrecan.	xanthohumol	31-33	matrix metallopeptidase 3	Homo sapiens	247-256
34017261-7	2021	In this article, we found that XH significantly inhibited inflammatory responses, attenuated catabolic enzymes expression, and ameliorated ECM degradation, as showed by decreased production of NO, PGE2, TNFalpha, and IL-6, decreased expression of MMP-3/-13 and ADAMTS-4/-5, and increased expression of collagen-II and aggrecan.	xanthohumol	31-33	ADAM metallopeptidase with thrombospondin type 1 motif 4	Homo sapiens	261-269
34017261-10	2021	HO-1 knockdown could abrogate the protective effects of XH in IL-1beta-treated chondrocytes.	xanthohumol	56-58	heme oxygenase 1	Homo sapiens	0-4
34017261-10	2021	HO-1 knockdown could abrogate the protective effects of XH in IL-1beta-treated chondrocytes.	xanthohumol	56-58	interleukin 1 alpha	Homo sapiens	62-70
35259468-0	2022	Xanthohumol inhibits non-small cell lung cancer by activating PUMA-mediated apoptosis.	xanthohumol	0-11	BCL2 binding component 3	Homo sapiens	62-66
35259468-7	2022	Xanthohumol activated mitochondrial apoptosis through upregulation of (p53-upregulated modulator of apoptosis) PUMA expression.	xanthohumol	0-11	tumor protein p53	Homo sapiens	71-74
35259468-7	2022	Xanthohumol activated mitochondrial apoptosis through upregulation of (p53-upregulated modulator of apoptosis) PUMA expression.	xanthohumol	0-11	BCL2 binding component 3	Homo sapiens	111-115
35259468-8	2022	After Xanthohumol treatment, the Akt activity was inhibited, which resulted in dephosphorylation of FOXO3a and PUMA induction.	xanthohumol	6-17	AKT serine/threonine kinase 1	Homo sapiens	33-36
35259468-8	2022	After Xanthohumol treatment, the Akt activity was inhibited, which resulted in dephosphorylation of FOXO3a and PUMA induction.	xanthohumol	6-17	forkhead box O3	Homo sapiens	100-106
35259468-8	2022	After Xanthohumol treatment, the Akt activity was inhibited, which resulted in dephosphorylation of FOXO3a and PUMA induction.	xanthohumol	6-17	BCL2 binding component 3	Homo sapiens	111-115
35259468-9	2022	Silent PUMA or FOXO3a impaired Xanthohumol-induced apoptosis in NSCLC cells.	xanthohumol	31-42	BCL2 binding component 3	Homo sapiens	7-11
35259468-9	2022	Silent PUMA or FOXO3a impaired Xanthohumol-induced apoptosis in NSCLC cells.	xanthohumol	31-42	forkhead box O3	Homo sapiens	15-21
35259468-10	2022	In nude mice, Xanthohumol administration suppressed NSCLC xenograft tumor growth and increased PUMA expression in tumor tissues.	xanthohumol	14-25	BCL2 binding component 3	Mus musculus	95-99
35259468-11	2022	Briefly, our studies revealed a novel mechanism by which Xanthohumol exerted its anti-tumor activity in a PUMA-dependent manner in NSCLC cells.	xanthohumol	57-68	BCL2 binding component 3	Mus musculus	106-110
35209070-7	2022	Differential microflora Gammaproteobacteria were significantly enriched in APP/PS1 mice treated with Xn.	xanthohumol	101-103	presenilin 1	Mus musculus	79-82
33998613-1	2021	This paper reports the obtention of amorphous solid dispersions (ASDs) of xanthohumol (XH) in PCL containing up to 50 wt% of the bioactive compound in the amorphous form thanks to the advantageous specific interactions established in this system.	xanthohumol	74-85	PHD finger protein 1	Homo sapiens	94-97
33998613-1	2021	This paper reports the obtention of amorphous solid dispersions (ASDs) of xanthohumol (XH) in PCL containing up to 50 wt% of the bioactive compound in the amorphous form thanks to the advantageous specific interactions established in this system.	xanthohumol	87-89	PHD finger protein 1	Homo sapiens	94-97
33998613-5	2021	FTIR spectroscopy reveals strong C[double bond, length as m-dash]OO-H specific interactions between the hydroxyl groups of XH and the carbonyl groups of PCL.	xanthohumol	123-125	PHD finger protein 1	Homo sapiens	153-156
33909081-0	2021	Xanthohumol ameliorates memory impairment and reduces the deposition of beta-amyloid in APP/PS1 mice via regulating the mTOR/LC3II and Bax/Bcl-2 signalling pathways.	xanthohumol	0-11	presenilin 1	Mus musculus	92-95
33909081-0	2021	Xanthohumol ameliorates memory impairment and reduces the deposition of beta-amyloid in APP/PS1 mice via regulating the mTOR/LC3II and Bax/Bcl-2 signalling pathways.	xanthohumol	0-11	mechanistic target of rapamycin kinase	Mus musculus	120-124
33909081-0	2021	Xanthohumol ameliorates memory impairment and reduces the deposition of beta-amyloid in APP/PS1 mice via regulating the mTOR/LC3II and Bax/Bcl-2 signalling pathways.	xanthohumol	0-11	BCL2-associated X protein	Mus musculus	135-138
33909081-0	2021	Xanthohumol ameliorates memory impairment and reduces the deposition of beta-amyloid in APP/PS1 mice via regulating the mTOR/LC3II and Bax/Bcl-2 signalling pathways.	xanthohumol	0-11	B cell leukemia/lymphoma 2	Mus musculus	139-144
33909081-2	2021	In this study, we investigated whether Xanthohumol could ameliorate memory impairment of APP/PS1 mice, and explored its potential mechanism of action.	xanthohumol	39-50	presenilin 1	Mus musculus	93-96
33909081-8	2021	Additionally, Xanthohumol increased superoxide dismutase level and reduced Interleukin-6 and Interleukin-1beta levels both in serum and hippocampus.	xanthohumol	14-25	interleukin 6	Mus musculus	75-88
33909081-8	2021	Additionally, Xanthohumol increased superoxide dismutase level and reduced Interleukin-6 and Interleukin-1beta levels both in serum and hippocampus.	xanthohumol	14-25	interleukin 1 beta	Mus musculus	93-110
33909081-9	2021	Xanthohumol also significantly reduced Abeta deposition in the hippocampus and activated autophagy and anti-apoptotic signals.	xanthohumol	0-11	amyloid beta (A4) precursor protein	Mus musculus	39-44
33909081-10	2021	CONCLUSIONS: Xanthohumol effectively ameliorates memory impairment of APP/PS1 mice by activating mTOR/LC3 and Bax/Bcl-2 signalling pathways, which provides new insight into the neuroprotective effects of Xanthohumol.	xanthohumol	13-24	presenilin 1	Mus musculus	74-77
33909081-10	2021	CONCLUSIONS: Xanthohumol effectively ameliorates memory impairment of APP/PS1 mice by activating mTOR/LC3 and Bax/Bcl-2 signalling pathways, which provides new insight into the neuroprotective effects of Xanthohumol.	xanthohumol	13-24	mechanistic target of rapamycin kinase	Mus musculus	97-101
33909081-10	2021	CONCLUSIONS: Xanthohumol effectively ameliorates memory impairment of APP/PS1 mice by activating mTOR/LC3 and Bax/Bcl-2 signalling pathways, which provides new insight into the neuroprotective effects of Xanthohumol.	xanthohumol	13-24	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	102-105
33909081-10	2021	CONCLUSIONS: Xanthohumol effectively ameliorates memory impairment of APP/PS1 mice by activating mTOR/LC3 and Bax/Bcl-2 signalling pathways, which provides new insight into the neuroprotective effects of Xanthohumol.	xanthohumol	13-24	BCL2-associated X protein	Mus musculus	110-113
33909081-10	2021	CONCLUSIONS: Xanthohumol effectively ameliorates memory impairment of APP/PS1 mice by activating mTOR/LC3 and Bax/Bcl-2 signalling pathways, which provides new insight into the neuroprotective effects of Xanthohumol.	xanthohumol	13-24	B cell leukemia/lymphoma 2	Mus musculus	114-119
33959012-8	2021	Collectively, these data indicated sex-dependent relationship between FXR, lipids and BAs, and suggest that XN ameliorates HFD-induced liver dysfunction via FXR-dependent and independent signaling.	xanthohumol	108-110	nuclear receptor subfamily 1, group H, member 4	Mus musculus	157-160
33959012-0	2021	Xanthohumol ameliorates Diet-Induced Liver Dysfunction via Farnesoid X Receptor-Dependent and Independent Signaling.	xanthohumol	0-11	nuclear receptor subfamily 1, group H, member 4	Mus musculus	59-79
33572775-8	2021	Subtoxic XN doses also induced markers of endoplasmic reticulum stress but inhibited the phosphorylation of the protumorigenic c-Jun N-terminal kinases (JNK).	xanthohumol	9-11	mitogen-activated protein kinase 8	Mus musculus	127-151
33672038-1	2021	Our previous study found that desmethylxanthohumol (1) inhibited alpha-glucosidase in vitro.	xanthohumol	30-50	sucrase-isomaltase	Homo sapiens	65-82
33572775-8	2021	Subtoxic XN doses also induced markers of endoplasmic reticulum stress but inhibited the phosphorylation of the protumorigenic c-Jun N-terminal kinases (JNK).	xanthohumol	9-11	mitogen-activated protein kinase 8	Mus musculus	153-156
33572775-11	2021	Metastases formed in the liver of XN-treated mice revealed significantly larger areas of central necrosis and lower Ki67 expression scores compared to that of control mice.	xanthohumol	34-36	antigen identified by monoclonal antibody Ki 67	Mus musculus	116-120
33127362-0	2021	Xanthohumol attenuates isoprenaline-induced cardiac hypertrophy and fibrosis through regulating PTEN/AKT/mTOR pathway.	xanthohumol	0-11	phosphatase and tensin homolog	Mus musculus	96-100
33127362-0	2021	Xanthohumol attenuates isoprenaline-induced cardiac hypertrophy and fibrosis through regulating PTEN/AKT/mTOR pathway.	xanthohumol	0-11	thymoma viral proto-oncogene 1	Mus musculus	101-104
33127362-0	2021	Xanthohumol attenuates isoprenaline-induced cardiac hypertrophy and fibrosis through regulating PTEN/AKT/mTOR pathway.	xanthohumol	0-11	mechanistic target of rapamycin kinase	Mus musculus	105-109
33127362-9	2021	We found that Xn administration up-regulated PTEN expression and inhibited the phosphorylation of AKT/mTOR in ISO-treated mice.	xanthohumol	14-16	phosphatase and tensin homolog	Mus musculus	45-49
33127362-9	2021	We found that Xn administration up-regulated PTEN expression and inhibited the phosphorylation of AKT/mTOR in ISO-treated mice.	xanthohumol	14-16	thymoma viral proto-oncogene 1	Mus musculus	98-101
33127362-9	2021	We found that Xn administration up-regulated PTEN expression and inhibited the phosphorylation of AKT/mTOR in ISO-treated mice.	xanthohumol	14-16	mechanistic target of rapamycin kinase	Mus musculus	102-106
33127362-10	2021	Moreover, treating with VO-ohpic, a specific PTEN inhibitor, abolished the cardioprotective effect of Xn.	xanthohumol	102-104	phosphatase and tensin homolog	Mus musculus	45-49
33127362-11	2021	Collectively, these results suggested that Xn attenuated ISO-induced cardiac hypertrophy and fibrosis through regulating PTEN/AKT/mTOR pathway.	xanthohumol	43-45	phosphatase and tensin homolog	Mus musculus	121-125
33127362-11	2021	Collectively, these results suggested that Xn attenuated ISO-induced cardiac hypertrophy and fibrosis through regulating PTEN/AKT/mTOR pathway.	xanthohumol	43-45	thymoma viral proto-oncogene 1	Mus musculus	126-129
33127362-11	2021	Collectively, these results suggested that Xn attenuated ISO-induced cardiac hypertrophy and fibrosis through regulating PTEN/AKT/mTOR pathway.	xanthohumol	43-45	mechanistic target of rapamycin kinase	Mus musculus	130-134
33431034-11	2021	In addition to pBD3, other porcine HDP genes such as pBD2, PG1-5, and pEP2C were induced to different magnitudes by xanthohumol, deoxyshikonin, isorhapontigenin, and calycosin, although clear gene- and cell type-specific patterns of regulation were observed.	xanthohumol	116-127	defensin beta 1	Sus scrofa	53-57
33431034-11	2021	In addition to pBD3, other porcine HDP genes such as pBD2, PG1-5, and pEP2C were induced to different magnitudes by xanthohumol, deoxyshikonin, isorhapontigenin, and calycosin, although clear gene- and cell type-specific patterns of regulation were observed.	xanthohumol	116-127	protegrin-1	Sus scrofa	59-64
32945473-4	2020	Of note, the natural product xanthohumol (Xanth) inhibited NSCLC cells via the downregulation of cyclin D1.	xanthohumol	42-47	cyclin D1	Homo sapiens	97-106
33036258-12	2020	Moreover, overexpression of osteogenic transcription factors bone morphogenetic protein 2 (BMP-2) and runt-related transcription factor 2 (Runx2) were significantly suppressed by XN treatment in VC.	xanthohumol	179-181	bone morphogenetic protein 2	Rattus norvegicus	61-89
33036258-12	2020	Moreover, overexpression of osteogenic transcription factors bone morphogenetic protein 2 (BMP-2) and runt-related transcription factor 2 (Runx2) were significantly suppressed by XN treatment in VC.	xanthohumol	179-181	bone morphogenetic protein 2	Rattus norvegicus	91-96
33036258-12	2020	Moreover, overexpression of osteogenic transcription factors bone morphogenetic protein 2 (BMP-2) and runt-related transcription factor 2 (Runx2) were significantly suppressed by XN treatment in VC.	xanthohumol	179-181	RUNX family transcription factor 2	Rattus norvegicus	102-137
33036258-12	2020	Moreover, overexpression of osteogenic transcription factors bone morphogenetic protein 2 (BMP-2) and runt-related transcription factor 2 (Runx2) were significantly suppressed by XN treatment in VC.	xanthohumol	179-181	RUNX family transcription factor 2	Rattus norvegicus	139-144
33036258-13	2020	Moreover, downregulation of vascular phenotypic markers alpha-smooth muscle actin (alpha-SMA) and smooth muscle 22 alpha (SM22alpha) were increased by XN treatment in VC.	xanthohumol	151-153	actin gamma 2, smooth muscle	Rattus norvegicus	56-81
33036258-13	2020	Moreover, downregulation of vascular phenotypic markers alpha-smooth muscle actin (alpha-SMA) and smooth muscle 22 alpha (SM22alpha) were increased by XN treatment in VC.	xanthohumol	151-153	transgelin	Rattus norvegicus	122-131
33036258-15	2020	Otherwise, Kelch-like ECH-associated protein 1 (Keap1) was alleviated by XN treatment in VC.	xanthohumol	73-75	Kelch-like ECH-associated protein 1	Rattus norvegicus	11-46
33036258-15	2020	Otherwise, Kelch-like ECH-associated protein 1 (Keap1) was alleviated by XN treatment in VC.	xanthohumol	73-75	Kelch-like ECH-associated protein 1	Rattus norvegicus	48-53
33036258-16	2020	In conclusion, our findings suggested that XN enhances antioxidant capacity to improve VC by regulating the Nrf2/Keap1/HO-1 pathway.	xanthohumol	43-45	NFE2 like bZIP transcription factor 2	Rattus norvegicus	108-112
33036258-16	2020	In conclusion, our findings suggested that XN enhances antioxidant capacity to improve VC by regulating the Nrf2/Keap1/HO-1 pathway.	xanthohumol	43-45	Kelch-like ECH-associated protein 1	Rattus norvegicus	113-118
33036258-16	2020	In conclusion, our findings suggested that XN enhances antioxidant capacity to improve VC by regulating the Nrf2/Keap1/HO-1 pathway.	xanthohumol	43-45	heme oxygenase 1	Rattus norvegicus	119-123
32945473-4	2020	Of note, the natural product xanthohumol (Xanth) inhibited NSCLC cells via the downregulation of cyclin D1.	xanthohumol	29-40	cyclin D1	Homo sapiens	97-106
32945473-6	2020	Furthermore, suppression of ERK1/2 impaired Fra1 phosphorylation and enhanced Xanth-induced Fra1 ubiquitination and degradation.	xanthohumol	78-83	mitogen-activated protein kinase 3	Homo sapiens	28-34
32945473-6	2020	Furthermore, suppression of ERK1/2 impaired Fra1 phosphorylation and enhanced Xanth-induced Fra1 ubiquitination and degradation.	xanthohumol	78-83	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	92-96
32945473-7	2020	In addition, the S265D mutation compromised Xanth-induced Fra1 degradation.	xanthohumol	44-49	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	58-62
33015460-3	2020	Natural flavonoids, in this case xanthohumol (XN), have been reported to attenuate TCDD toxicity through inhibition of the transformation of the AhR.	xanthohumol	33-44	aryl hydrocarbon receptor	Homo sapiens	145-148
33015460-3	2020	Natural flavonoids, in this case xanthohumol (XN), have been reported to attenuate TCDD toxicity through inhibition of the transformation of the AhR.	xanthohumol	46-48	aryl hydrocarbon receptor	Homo sapiens	145-148
32422304-8	2020	Replication factor C subunit 2 (RFC2), a DNA repair-related gene, was obviously downregulated in XN-treated cells.	xanthohumol	97-99	replication factor C subunit 2	Homo sapiens	0-30
32422304-8	2020	Replication factor C subunit 2 (RFC2), a DNA repair-related gene, was obviously downregulated in XN-treated cells.	xanthohumol	97-99	replication factor C subunit 2	Homo sapiens	32-36
32422304-10	2020	Inhibition of RFC2 reduced cell viability, induced cell apoptosis, and enhanced both XN and TMZ cytotoxicity.	xanthohumol	85-87	replication factor C subunit 2	Homo sapiens	14-18
32422304-14	2020	SIGNIFICANCE: Consequently, we suggest that miR-4749-5p targeting RFC2 signaling participates in XN-enhanced TMZ cytotoxicity of GBM.	xanthohumol	97-99	microRNA 4749	Homo sapiens	44-52
32422304-14	2020	SIGNIFICANCE: Consequently, we suggest that miR-4749-5p targeting RFC2 signaling participates in XN-enhanced TMZ cytotoxicity of GBM.	xanthohumol	97-99	replication factor C subunit 2	Homo sapiens	66-70
32627931-4	2020	The authors previously reported that FXR agonist xanthohumol (XN), the principal prenylated flavonoid in hops (Humulus lupulus), and its hydrogenated derivatives, alpha,beta-dihydroxanthohumol (DXN), and tetrahydroxanthohumol (TXN), ameliorated obesity-mediated insulin resistance, and cognitive impairment in mice fed a high-fat diet.	xanthohumol	49-60	nuclear receptor subfamily 1, group H, member 4	Mus musculus	37-40
32627931-4	2020	The authors previously reported that FXR agonist xanthohumol (XN), the principal prenylated flavonoid in hops (Humulus lupulus), and its hydrogenated derivatives, alpha,beta-dihydroxanthohumol (DXN), and tetrahydroxanthohumol (TXN), ameliorated obesity-mediated insulin resistance, and cognitive impairment in mice fed a high-fat diet.	xanthohumol	62-64	nuclear receptor subfamily 1, group H, member 4	Mus musculus	37-40
31793596-0	2019	Xanthohumol inhibits tau protein aggregation and protects cells against tau aggregates.	xanthohumol	0-11	microtubule associated protein tau	Homo sapiens	21-24
32509787-0	2020	Xanthohumol Inhibits the Growth of Keratin 18-Overexpressed Esophageal Squamous Cell Carcinoma in vitro and in vivo.	xanthohumol	0-11	keratin 18	Homo sapiens	35-45
32509787-6	2020	Using xanthohumol-sepharose conjugated bead pull-down and mass/mass analysis, we found that KRT18 is a novel target of xanthohumol in KYSE30 cells.	xanthohumol	6-17	keratin 18	Homo sapiens	92-97
32509787-6	2020	Using xanthohumol-sepharose conjugated bead pull-down and mass/mass analysis, we found that KRT18 is a novel target of xanthohumol in KYSE30 cells.	xanthohumol	119-130	keratin 18	Homo sapiens	92-97
32509787-8	2020	Anti-proliferative activity of xanthohumol was abrogated or enhanced according to the knockdown or overexpression of KRT18 protein, respectively.	xanthohumol	31-42	keratin 18	Homo sapiens	117-122
32509787-9	2020	Xanthohumol also induced apoptosis and cell cycle arrest at G1 phase which was associated with the modulation of expression of related makers including cyclin D1, cyclin D3, and cleaved-PARP, Bcl-2, cytochrome c and Bax.	xanthohumol	0-11	cyclin D1	Homo sapiens	152-161
32509787-9	2020	Xanthohumol also induced apoptosis and cell cycle arrest at G1 phase which was associated with the modulation of expression of related makers including cyclin D1, cyclin D3, and cleaved-PARP, Bcl-2, cytochrome c and Bax.	xanthohumol	0-11	cyclin D3	Homo sapiens	163-172
32509787-9	2020	Xanthohumol also induced apoptosis and cell cycle arrest at G1 phase which was associated with the modulation of expression of related makers including cyclin D1, cyclin D3, and cleaved-PARP, Bcl-2, cytochrome c and Bax.	xanthohumol	0-11	collagen type XI alpha 2 chain	Homo sapiens	186-190
32509787-9	2020	Xanthohumol also induced apoptosis and cell cycle arrest at G1 phase which was associated with the modulation of expression of related makers including cyclin D1, cyclin D3, and cleaved-PARP, Bcl-2, cytochrome c and Bax.	xanthohumol	0-11	BCL2 apoptosis regulator	Homo sapiens	192-197
32509787-9	2020	Xanthohumol also induced apoptosis and cell cycle arrest at G1 phase which was associated with the modulation of expression of related makers including cyclin D1, cyclin D3, and cleaved-PARP, Bcl-2, cytochrome c and Bax.	xanthohumol	0-11	cytochrome c, somatic	Homo sapiens	199-211
32509787-9	2020	Xanthohumol also induced apoptosis and cell cycle arrest at G1 phase which was associated with the modulation of expression of related makers including cyclin D1, cyclin D3, and cleaved-PARP, Bcl-2, cytochrome c and Bax.	xanthohumol	0-11	BCL2 associated X, apoptosis regulator	Homo sapiens	216-219
32509787-10	2020	While xanthohumol attenuated KRT18 protein expression, it failed to cause any change in the KRT18 mRNA level.	xanthohumol	6-17	keratin 18	Homo sapiens	29-34
32509787-11	2020	Furthermore, oral administration of xanthohumol decreased tumor volume and weight in patient-derived xenografts (PDXs) tumors having overexpressed KRT18.	xanthohumol	36-47	keratin 18	Homo sapiens	147-152
32509787-12	2020	Overall these results suggest that xanthohumol acts as a KRT18 regulator to suppress the growth of ESCC.	xanthohumol	35-46	keratin 18	Homo sapiens	57-62
32410646-8	2020	Xanthohumol inhibited the Akt-Wee1-CDK1 signaling, which in turn decreased survivin phosphorylation on Thr34, and facilitated E3 ligase Fbxl7-mediated survivin ubiquitination and degradation.	xanthohumol	0-11	AKT serine/threonine kinase 1	Homo sapiens	26-29
32410646-8	2020	Xanthohumol inhibited the Akt-Wee1-CDK1 signaling, which in turn decreased survivin phosphorylation on Thr34, and facilitated E3 ligase Fbxl7-mediated survivin ubiquitination and degradation.	xanthohumol	0-11	WEE1 G2 checkpoint kinase	Homo sapiens	30-34
32410646-8	2020	Xanthohumol inhibited the Akt-Wee1-CDK1 signaling, which in turn decreased survivin phosphorylation on Thr34, and facilitated E3 ligase Fbxl7-mediated survivin ubiquitination and degradation.	xanthohumol	0-11	cyclin dependent kinase 1	Homo sapiens	35-39
32410646-8	2020	Xanthohumol inhibited the Akt-Wee1-CDK1 signaling, which in turn decreased survivin phosphorylation on Thr34, and facilitated E3 ligase Fbxl7-mediated survivin ubiquitination and degradation.	xanthohumol	0-11	F-box and leucine rich repeat protein 7	Homo sapiens	136-141
32070777-0	2020	Combination of xanthohumol and phenethyl isothiocyanate inhibits NF-kappaB and activates Nrf2 in pancreatic cancer cells.	xanthohumol	15-26	NFE2 like bZIP transcription factor 2	Homo sapiens	89-93
32070777-3	2020	Thus, the aim of this study was to evaluate and compare the effect of PEITC, I3C, XAN, and RES and their combinations on the expression and activation of NF-kappaB and Nrf2 in human PC cell line PANC-1.	xanthohumol	82-85	NFE2 like bZIP transcription factor 2	Homo sapiens	168-172
32070777-4	2020	The combination of XAN and PEITC was more efficient than the single compounds in reducing the binding of NF-kappaB p65 subunits by 47-60% and expression of p65 gene by 28-48%.	xanthohumol	19-22	RELA proto-oncogene, NF-kB subunit	Homo sapiens	115-118
32070777-4	2020	The combination of XAN and PEITC was more efficient than the single compounds in reducing the binding of NF-kappaB p65 subunits by 47-60% and expression of p65 gene by 28-48%.	xanthohumol	19-22	RELA proto-oncogene, NF-kB subunit	Homo sapiens	156-159
32070777-5	2020	The combination of XAN and PEITC also enhanced the activation and expression of Nrf2 and subsequently the expression of GSTP, NQO1, and SOD genes which are controlled by this transcription factor.	xanthohumol	19-22	NFE2 like bZIP transcription factor 2	Homo sapiens	80-84
32070777-5	2020	The combination of XAN and PEITC also enhanced the activation and expression of Nrf2 and subsequently the expression of GSTP, NQO1, and SOD genes which are controlled by this transcription factor.	xanthohumol	19-22	glutathione S-transferase pi 1	Homo sapiens	120-124
32070777-5	2020	The combination of XAN and PEITC also enhanced the activation and expression of Nrf2 and subsequently the expression of GSTP, NQO1, and SOD genes which are controlled by this transcription factor.	xanthohumol	19-22	NAD(P)H quinone dehydrogenase 1	Homo sapiens	126-130
32070777-6	2020	Modulation of the activity of NF-kappaB and Nrf2 by the combination of XAN and PEITC was found to lead to reduced proliferation of PANC-1 cells.	xanthohumol	71-74	NFE2 like bZIP transcription factor 2	Homo sapiens	44-48
32368287-0	2020	Xanthohumol suppresses glioblastoma via modulation of Hexokinase 2 -mediated glycolysis.	xanthohumol	0-11	hexokinase 2	Homo sapiens	54-66
32368287-3	2020	Xanthohumol suppressed cell proliferation and colony formation of GBM cells, and significantly impaired glucose metabolism via inhibiting Hexokinase 2 (HK2) expression.	xanthohumol	0-11	hexokinase 2	Homo sapiens	138-150
32368287-3	2020	Xanthohumol suppressed cell proliferation and colony formation of GBM cells, and significantly impaired glucose metabolism via inhibiting Hexokinase 2 (HK2) expression.	xanthohumol	0-11	hexokinase 2	Homo sapiens	152-155
32368287-4	2020	We demonstrated that down-regulation of c-Myc was required for xanthohumol-induced decrease of HK2.	xanthohumol	63-74	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	40-45
32368287-4	2020	We demonstrated that down-regulation of c-Myc was required for xanthohumol-induced decrease of HK2.	xanthohumol	63-74	hexokinase 2	Homo sapiens	95-98
32368287-5	2020	Xanthohumol destabilization of c-Myc, and promoted FBW7-mediated ubiquitination of c-Myc.	xanthohumol	0-11	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	31-36
32368287-5	2020	Xanthohumol destabilization of c-Myc, and promoted FBW7-mediated ubiquitination of c-Myc.	xanthohumol	0-11	F-box and WD repeat domain containing 7	Homo sapiens	51-55
32368287-6	2020	Xanthohumol attenuated Akt activity and inhibited the activation of GSK3beta, resulted in c-Myc degradation.	xanthohumol	0-11	AKT serine/threonine kinase 1	Homo sapiens	23-26
32368287-6	2020	Xanthohumol attenuated Akt activity and inhibited the activation of GSK3beta, resulted in c-Myc degradation.	xanthohumol	0-11	glycogen synthase kinase 3 alpha	Homo sapiens	68-76
32368287-6	2020	Xanthohumol attenuated Akt activity and inhibited the activation of GSK3beta, resulted in c-Myc degradation.	xanthohumol	0-11	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	90-95
32368287-7	2020	Overexpression of Myr-Akt1 significantly rescued xanthohumol-mediated c-Myc inhibition and glycolysis suppression.	xanthohumol	49-60	AKT serine/threonine kinase 1	Homo sapiens	22-26
32368287-7	2020	Overexpression of Myr-Akt1 significantly rescued xanthohumol-mediated c-Myc inhibition and glycolysis suppression.	xanthohumol	49-60	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	70-75
32368287-8	2020	Finally, the xanthohumol-mediated down-regulation of the PI3-K/Akt-GSK3beta-FBW7 signaling axis promoted the destabilization of c-Myc.	xanthohumol	13-24	AKT serine/threonine kinase 1	Homo sapiens	63-66
32368287-8	2020	Finally, the xanthohumol-mediated down-regulation of the PI3-K/Akt-GSK3beta-FBW7 signaling axis promoted the destabilization of c-Myc.	xanthohumol	13-24	glycogen synthase kinase 3 alpha	Homo sapiens	67-75
32368287-8	2020	Finally, the xanthohumol-mediated down-regulation of the PI3-K/Akt-GSK3beta-FBW7 signaling axis promoted the destabilization of c-Myc.	xanthohumol	13-24	F-box and WD repeat domain containing 7	Homo sapiens	76-80
32368287-8	2020	Finally, the xanthohumol-mediated down-regulation of the PI3-K/Akt-GSK3beta-FBW7 signaling axis promoted the destabilization of c-Myc.	xanthohumol	13-24	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	128-133
31816340-5	2020	Xanthohumol (10 or 50 mg/kg) administrated intraperitoneally 30 min prior to KA (15 mg/kg) considerably ameliorated KA-induced seizures, glutamate concentration elevation, and CA3 neuron death.	xanthohumol	0-11	carbonic anhydrase 3	Rattus norvegicus	176-179
31816340-6	2020	The decrease of mitochondrial fusion protein Mfn-2 and antiapoptotic protein Bcl-2 expression in hippocampal tissues following KA injection were reversed by xanthohumol.	xanthohumol	157-168	mitofusin 2	Rattus norvegicus	45-50
31816340-6	2020	The decrease of mitochondrial fusion protein Mfn-2 and antiapoptotic protein Bcl-2 expression in hippocampal tissues following KA injection were reversed by xanthohumol.	xanthohumol	157-168	BCL2, apoptosis regulator	Rattus norvegicus	77-82
31816340-7	2020	Moreover, apoptotic protease activating factor 1 (Apaf-1) expression and caspase-3 activation in the hippocampus were inhibited by xanthohumol.	xanthohumol	131-142	apoptotic peptidase activating factor 1	Rattus norvegicus	10-48
31816340-7	2020	Moreover, apoptotic protease activating factor 1 (Apaf-1) expression and caspase-3 activation in the hippocampus were inhibited by xanthohumol.	xanthohumol	131-142	apoptotic peptidase activating factor 1	Rattus norvegicus	50-56
31816340-7	2020	Moreover, apoptotic protease activating factor 1 (Apaf-1) expression and caspase-3 activation in the hippocampus were inhibited by xanthohumol.	xanthohumol	131-142	caspase 3	Rattus norvegicus	73-82
31816340-8	2020	These results suggest that xanthohumol up-regulates Mfn-2 and Bcl-2 to preserve mitochondrial function and suppress Apaf-1 and caspase-3 activation, thereby increasing neuron survival in rats after KA treatment.	xanthohumol	27-38	mitofusin 2	Rattus norvegicus	52-57
31816340-8	2020	These results suggest that xanthohumol up-regulates Mfn-2 and Bcl-2 to preserve mitochondrial function and suppress Apaf-1 and caspase-3 activation, thereby increasing neuron survival in rats after KA treatment.	xanthohumol	27-38	BCL2, apoptosis regulator	Rattus norvegicus	62-67
31816340-8	2020	These results suggest that xanthohumol up-regulates Mfn-2 and Bcl-2 to preserve mitochondrial function and suppress Apaf-1 and caspase-3 activation, thereby increasing neuron survival in rats after KA treatment.	xanthohumol	27-38	apoptotic peptidase activating factor 1	Rattus norvegicus	116-122
31816340-8	2020	These results suggest that xanthohumol up-regulates Mfn-2 and Bcl-2 to preserve mitochondrial function and suppress Apaf-1 and caspase-3 activation, thereby increasing neuron survival in rats after KA treatment.	xanthohumol	27-38	caspase 3	Rattus norvegicus	127-136
31793596-0	2019	Xanthohumol inhibits tau protein aggregation and protects cells against tau aggregates.	xanthohumol	0-11	microtubule associated protein tau	Homo sapiens	72-75
31793596-4	2019	In this study, xanthohumol (XN), a natural botanic compound, is found to inhibit tau protein aggregation and disaggregate tau fibrils.	xanthohumol	15-26	microtubule associated protein tau	Homo sapiens	81-84
31793596-4	2019	In this study, xanthohumol (XN), a natural botanic compound, is found to inhibit tau protein aggregation and disaggregate tau fibrils.	xanthohumol	15-26	microtubule associated protein tau	Homo sapiens	122-125
31793596-4	2019	In this study, xanthohumol (XN), a natural botanic compound, is found to inhibit tau protein aggregation and disaggregate tau fibrils.	xanthohumol	28-30	microtubule associated protein tau	Homo sapiens	81-84
31793596-4	2019	In this study, xanthohumol (XN), a natural botanic compound, is found to inhibit tau protein aggregation and disaggregate tau fibrils.	xanthohumol	28-30	microtubule associated protein tau	Homo sapiens	122-125
31386885-0	2019	Xanthohumol exhibits anti-myeloma activity in vitro through inhibition of cell proliferation, induction of apoptosis via the ERK and JNK-dependent mechanism, and suppression of sIL-6R and VEGF production.	xanthohumol	0-11	mitogen-activated protein kinase 1	Homo sapiens	125-128
31812985-10	2019	Interestingly, the Nrf2 inhibitor blocked xanthohumol but not quercetin-mediated neuroprotection.	xanthohumol	42-53	NFE2 like bZIP transcription factor 2	Homo sapiens	19-23
31386885-0	2019	Xanthohumol exhibits anti-myeloma activity in vitro through inhibition of cell proliferation, induction of apoptosis via the ERK and JNK-dependent mechanism, and suppression of sIL-6R and VEGF production.	xanthohumol	0-11	mitogen-activated protein kinase 8	Homo sapiens	133-136
31386885-10	2019	The apoptotic process was probably mediated via ROS overproduction and MAPK (ERK and JNK) activation as N-acetylcysteine, or specific inhibitors of these kinases prevented the XN-induced caspase-3 activity and, hence, apoptosis.	xanthohumol	176-178	mitogen-activated protein kinase 8	Homo sapiens	85-88
31386885-10	2019	The apoptotic process was probably mediated via ROS overproduction and MAPK (ERK and JNK) activation as N-acetylcysteine, or specific inhibitors of these kinases prevented the XN-induced caspase-3 activity and, hence, apoptosis.	xanthohumol	176-178	caspase 3	Homo sapiens	187-196
31386885-0	2019	Xanthohumol exhibits anti-myeloma activity in vitro through inhibition of cell proliferation, induction of apoptosis via the ERK and JNK-dependent mechanism, and suppression of sIL-6R and VEGF production.	xanthohumol	0-11	vascular endothelial growth factor A	Homo sapiens	188-192
31386885-12	2019	CONCLUSIONS: ERK and JNK signaling pathways are involved in XN-induced cytotoxicity against MM cells.	xanthohumol	60-62	mitogen-activated protein kinase 1	Homo sapiens	13-16
31386885-9	2019	The marked apoptosis induction in the XN-treated RPMI8226 cells was related to initiation of mitochondrial and extrinsic pathways, as indicated by the altered p53, Bax, and Bcl-2 protein expression, cleavage of procaspase 8 and 9, and elevated caspase-3 activity.	xanthohumol	38-40	tumor protein p53	Homo sapiens	159-162
31386885-12	2019	CONCLUSIONS: ERK and JNK signaling pathways are involved in XN-induced cytotoxicity against MM cells.	xanthohumol	60-62	mitogen-activated protein kinase 8	Homo sapiens	21-24
31386885-9	2019	The marked apoptosis induction in the XN-treated RPMI8226 cells was related to initiation of mitochondrial and extrinsic pathways, as indicated by the altered p53, Bax, and Bcl-2 protein expression, cleavage of procaspase 8 and 9, and elevated caspase-3 activity.	xanthohumol	38-40	BCL2 associated X, apoptosis regulator	Homo sapiens	164-167
31386885-9	2019	The marked apoptosis induction in the XN-treated RPMI8226 cells was related to initiation of mitochondrial and extrinsic pathways, as indicated by the altered p53, Bax, and Bcl-2 protein expression, cleavage of procaspase 8 and 9, and elevated caspase-3 activity.	xanthohumol	38-40	BCL2 apoptosis regulator	Homo sapiens	173-178
31386885-9	2019	The marked apoptosis induction in the XN-treated RPMI8226 cells was related to initiation of mitochondrial and extrinsic pathways, as indicated by the altered p53, Bax, and Bcl-2 protein expression, cleavage of procaspase 8 and 9, and elevated caspase-3 activity.	xanthohumol	38-40	caspase 3	Homo sapiens	244-253
31386885-10	2019	The apoptotic process was probably mediated via ROS overproduction and MAPK (ERK and JNK) activation as N-acetylcysteine, or specific inhibitors of these kinases prevented the XN-induced caspase-3 activity and, hence, apoptosis.	xanthohumol	176-178	mitogen-activated protein kinase 1	Homo sapiens	71-75
31386885-10	2019	The apoptotic process was probably mediated via ROS overproduction and MAPK (ERK and JNK) activation as N-acetylcysteine, or specific inhibitors of these kinases prevented the XN-induced caspase-3 activity and, hence, apoptosis.	xanthohumol	176-178	mitogen-activated protein kinase 1	Homo sapiens	77-80
31648725-4	2019	In our previous study, Xanthohumol (Xn), a prenylated flavonoid extracted for hops (Humulus lupulus L), was screened from 386 natural products to inhibit PRRSV proliferation and alleviate oxidative stress induced by PRRSV via the Nrf2-HMOX1 axis in Marc-145 cells.	xanthohumol	23-34	NFE2 like bZIP transcription factor 2	Homo sapiens	230-234
31983118-10	2019	Xanthohumol also caused activation of caspase-3 and 9 and increased the Bax/Bcl-2 ratio.	xanthohumol	0-11	caspase 3	Homo sapiens	38-47
31983118-10	2019	Xanthohumol also caused activation of caspase-3 and 9 and increased the Bax/Bcl-2 ratio.	xanthohumol	0-11	BCL2 associated X, apoptosis regulator	Homo sapiens	72-75
31983118-10	2019	Xanthohumol also caused activation of caspase-3 and 9 and increased the Bax/Bcl-2 ratio.	xanthohumol	0-11	BCL2 apoptosis regulator	Homo sapiens	76-81
31983118-13	2019	The effects of Xanthohumol were also investigated on the Ras/MEK/ERK signalling pathway which revealed that Xanthohumol also blocks the MEK/ERK signalling pathway in colon cancer cells in a concentration-dependent manner.	xanthohumol	108-119	mitogen-activated protein kinase kinase 7	Homo sapiens	61-64
31983118-13	2019	The effects of Xanthohumol were also investigated on the Ras/MEK/ERK signalling pathway which revealed that Xanthohumol also blocks the MEK/ERK signalling pathway in colon cancer cells in a concentration-dependent manner.	xanthohumol	108-119	mitogen-activated protein kinase 1	Homo sapiens	65-68
31983118-13	2019	The effects of Xanthohumol were also investigated on the Ras/MEK/ERK signalling pathway which revealed that Xanthohumol also blocks the MEK/ERK signalling pathway in colon cancer cells in a concentration-dependent manner.	xanthohumol	108-119	mitogen-activated protein kinase kinase 7	Homo sapiens	136-139
31983118-13	2019	The effects of Xanthohumol were also investigated on the Ras/MEK/ERK signalling pathway which revealed that Xanthohumol also blocks the MEK/ERK signalling pathway in colon cancer cells in a concentration-dependent manner.	xanthohumol	108-119	mitogen-activated protein kinase 1	Homo sapiens	140-143
31648725-4	2019	In our previous study, Xanthohumol (Xn), a prenylated flavonoid extracted for hops (Humulus lupulus L), was screened from 386 natural products to inhibit PRRSV proliferation and alleviate oxidative stress induced by PRRSV via the Nrf2-HMOX1 axis in Marc-145 cells.	xanthohumol	23-34	heme oxygenase 1	Homo sapiens	235-240
31648725-4	2019	In our previous study, Xanthohumol (Xn), a prenylated flavonoid extracted for hops (Humulus lupulus L), was screened from 386 natural products to inhibit PRRSV proliferation and alleviate oxidative stress induced by PRRSV via the Nrf2-HMOX1 axis in Marc-145 cells.	xanthohumol	36-38	NFE2 like bZIP transcription factor 2	Homo sapiens	230-234
31648725-4	2019	In our previous study, Xanthohumol (Xn), a prenylated flavonoid extracted for hops (Humulus lupulus L), was screened from 386 natural products to inhibit PRRSV proliferation and alleviate oxidative stress induced by PRRSV via the Nrf2-HMOX1 axis in Marc-145 cells.	xanthohumol	36-38	heme oxygenase 1	Homo sapiens	235-240
31525874-0	2019	Xanthohumol suppresses NPC1L1 gene expression through down-regulation of HNF-4alpha and inhibits cholesterol uptake in Caco-2 cells.	xanthohumol	0-11	NPC1 like intracellular cholesterol transporter 1	Homo sapiens	23-29
31525874-0	2019	Xanthohumol suppresses NPC1L1 gene expression through down-regulation of HNF-4alpha and inhibits cholesterol uptake in Caco-2 cells.	xanthohumol	0-11	hepatocyte nuclear factor 4 alpha	Homo sapiens	73-83
31527518-0	2019	Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells.	xanthohumol	0-11	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	100-107
30887517-5	2019	Xanthohumol significantly inhibited the AKT kinase activity in an ATP competitive manner, which was confirmed in binding and computational docking models.	xanthohumol	0-11	AKT serine/threonine kinase 1	Homo sapiens	40-43
31595166-3	2019	We demonstrated that the natural compound, xanthohumol, has a profound anti-tumor effect on CRC via down-regulation of HK2 and glycolysis.	xanthohumol	43-54	hexokinase 2	Homo sapiens	119-122
31595166-6	2019	Moreover, our results revealed that xanthohumol down-regulated the EGFR-Akt signaling, exogenous overexpression of constitutively activated Akt1 significantly impaired xanthohumol-induced glycolysis suppression and apoptosis induction.	xanthohumol	36-47	epidermal growth factor receptor	Homo sapiens	67-71
31595166-6	2019	Moreover, our results revealed that xanthohumol down-regulated the EGFR-Akt signaling, exogenous overexpression of constitutively activated Akt1 significantly impaired xanthohumol-induced glycolysis suppression and apoptosis induction.	xanthohumol	36-47	AKT serine/threonine kinase 1	Homo sapiens	72-75
31595166-6	2019	Moreover, our results revealed that xanthohumol down-regulated the EGFR-Akt signaling, exogenous overexpression of constitutively activated Akt1 significantly impaired xanthohumol-induced glycolysis suppression and apoptosis induction.	xanthohumol	168-179	epidermal growth factor receptor	Homo sapiens	67-71
31595166-6	2019	Moreover, our results revealed that xanthohumol down-regulated the EGFR-Akt signaling, exogenous overexpression of constitutively activated Akt1 significantly impaired xanthohumol-induced glycolysis suppression and apoptosis induction.	xanthohumol	168-179	AKT serine/threonine kinase 1	Homo sapiens	140-144
31506103-0	2019	Xanthohumol inhibits PRRSV proliferation and alleviates oxidative stress induced by PRRSV via the Nrf2-HMOX1 axis.	xanthohumol	0-11	NFE2 like bZIP transcription factor 2	Homo sapiens	98-102
31506103-0	2019	Xanthohumol inhibits PRRSV proliferation and alleviates oxidative stress induced by PRRSV via the Nrf2-HMOX1 axis.	xanthohumol	0-11	heme oxygenase 1	Homo sapiens	103-108
30887517-11	2019	Taken together, our data suggest that the inhibition of ESCC tumor growth with xanthohumol is caused by targeting AKT.	xanthohumol	79-90	AKT serine/threonine kinase 1	Homo sapiens	114-117
31116948-0	2019	Xanthohumol Analogues as Potent Nrf2 Activators against Oxidative Stress Mediated Damages of PC12 Cells.	xanthohumol	0-11	NFE2 like bZIP transcription factor 2	Rattus norvegicus	32-36
30849340-4	2019	The hop-derived prenylated chalcone xanthohumol (XN) and its physiological metabolites isoxanthohumol (IX) and 8-prenylnaringenin (8-PN) have previously been reported to inhibit other DAUN reducing reductases and dehydrogenases including AKR1B1 and AKR1B10.	xanthohumol	49-51	aldo-keto reductase family 1 member B	Homo sapiens	238-244
30849340-4	2019	The hop-derived prenylated chalcone xanthohumol (XN) and its physiological metabolites isoxanthohumol (IX) and 8-prenylnaringenin (8-PN) have previously been reported to inhibit other DAUN reducing reductases and dehydrogenases including AKR1B1 and AKR1B10.	xanthohumol	49-51	aldo-keto reductase family 1 member B10	Homo sapiens	249-256
30857300-3	2019	Here we show that DXN and TXN possess improved anti-proliferative activity compared with XN in two colon (HCT116, HT29) and two hepatocellular (HepG2, Huh7) carcinoma cell lines, as indicated by their respective IC50 values.	xanthohumol	19-21	MIR7-3 host gene	Homo sapiens	151-155
30870485-0	2019	Xanthohumol increases death receptor 5 expression and enhances apoptosis with the TNF-related apoptosis-inducing ligand in neuroblastoma cell lines.	xanthohumol	0-11	TNF superfamily member 10	Homo sapiens	82-119
30870485-12	2019	Therefore, this study shows XN treatment reduces NB cell growth via apoptosis in a dose-dependent manner, and enhanced growth reduction was observed in combination with TRAIL.	xanthohumol	28-30	TNF superfamily member 10	Homo sapiens	169-174
30870485-13	2019	This is the first study to demonstrate that XN alters the expression of DR5 as well as the synergistic effect of XN on TRAIL in NB and provides a strong rationale for further preclinical analysis.	xanthohumol	44-46	TNF receptor superfamily member 10b	Homo sapiens	72-75
30870485-13	2019	This is the first study to demonstrate that XN alters the expression of DR5 as well as the synergistic effect of XN on TRAIL in NB and provides a strong rationale for further preclinical analysis.	xanthohumol	113-115	TNF superfamily member 10	Homo sapiens	119-124
30857304-0	2019	Anti-Remodeling Effects of Xanthohumol-Fortified Beer in Pulmonary Arterial Hypertension Mediated by ERK and AKT Inhibition.	xanthohumol	27-38	Eph receptor B1	Rattus norvegicus	101-104
30857304-0	2019	Anti-Remodeling Effects of Xanthohumol-Fortified Beer in Pulmonary Arterial Hypertension Mediated by ERK and AKT Inhibition.	xanthohumol	27-38	AKT serine/threonine kinase 1	Rattus norvegicus	109-112
30119200-0	2018	Xanthohumol induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI3K/Akt/mTOR-kinase in human gastric cancer cells.	xanthohumol	0-11	BCL2 apoptosis regulator	Homo sapiens	68-73
30608650-11	2019	The weak electrophile, XH, can activate the Keap1-Nrf2 pathway and turn on the synthesis of detoxification enzymes such as NAD(P)H-quinone oxidoreductase 1 and glutathione S-transferase.	xanthohumol	23-25	kelch like ECH associated protein 1	Homo sapiens	44-49
30608650-11	2019	The weak electrophile, XH, can activate the Keap1-Nrf2 pathway and turn on the synthesis of detoxification enzymes such as NAD(P)H-quinone oxidoreductase 1 and glutathione S-transferase.	xanthohumol	23-25	NFE2 like bZIP transcription factor 2	Homo sapiens	50-54
30608650-11	2019	The weak electrophile, XH, can activate the Keap1-Nrf2 pathway and turn on the synthesis of detoxification enzymes such as NAD(P)H-quinone oxidoreductase 1 and glutathione S-transferase.	xanthohumol	23-25	NAD(P)H quinone dehydrogenase 1	Homo sapiens	123-155
30608650-11	2019	The weak electrophile, XH, can activate the Keap1-Nrf2 pathway and turn on the synthesis of detoxification enzymes such as NAD(P)H-quinone oxidoreductase 1 and glutathione S-transferase.	xanthohumol	23-25	glutathione S-transferase kappa 1	Homo sapiens	160-185
31453789-0	2019	Amyloid-beta Aggregation Inhibitory and Neuroprotective Effects of Xanthohumol and its Derivatives for Alzheimer"s Diseases.	xanthohumol	67-78	amyloid beta precursor protein	Homo sapiens	0-12
31453789-1	2019	BACKGROUND: Xanthohumol has been reported to have cytoprotection through activation of Nrf2-ARE signaling pathway and; it has capability of scavenging free radicals, suggesting its potential for the prevention of neurodegeneration.	xanthohumol	12-23	NFE2 like bZIP transcription factor 2	Homo sapiens	87-91
29532688-3	2018	Our results show that XN, IX and 8-PN are potent uncompetitive, tight-binding inhibitors of human aldose reductase AKR1B1 (Ki = 15.08 muM, 0.34 muM, 0.71 muM) and of human AKR1B10 (Ki = 20.11 muM, 2.25 muM, 1.95 muM).	xanthohumol	22-24	aldo-keto reductase family 1 member B	Homo sapiens	115-121
29532688-3	2018	Our results show that XN, IX and 8-PN are potent uncompetitive, tight-binding inhibitors of human aldose reductase AKR1B1 (Ki = 15.08 muM, 0.34 muM, 0.71 muM) and of human AKR1B10 (Ki = 20.11 muM, 2.25 muM, 1.95 muM).	xanthohumol	22-24	latexin	Homo sapiens	134-137
29532688-3	2018	Our results show that XN, IX and 8-PN are potent uncompetitive, tight-binding inhibitors of human aldose reductase AKR1B1 (Ki = 15.08 muM, 0.34 muM, 0.71 muM) and of human AKR1B10 (Ki = 20.11 muM, 2.25 muM, 1.95 muM).	xanthohumol	22-24	latexin	Homo sapiens	144-147
29532688-3	2018	Our results show that XN, IX and 8-PN are potent uncompetitive, tight-binding inhibitors of human aldose reductase AKR1B1 (Ki = 15.08 muM, 0.34 muM, 0.71 muM) and of human AKR1B10 (Ki = 20.11 muM, 2.25 muM, 1.95 muM).	xanthohumol	22-24	latexin	Homo sapiens	144-147
29532688-3	2018	Our results show that XN, IX and 8-PN are potent uncompetitive, tight-binding inhibitors of human aldose reductase AKR1B1 (Ki = 15.08 muM, 0.34 muM, 0.71 muM) and of human AKR1B10 (Ki = 20.11 muM, 2.25 muM, 1.95 muM).	xanthohumol	22-24	aldo-keto reductase family 1 member B10	Homo sapiens	172-179
29532688-3	2018	Our results show that XN, IX and 8-PN are potent uncompetitive, tight-binding inhibitors of human aldose reductase AKR1B1 (Ki = 15.08 muM, 0.34 muM, 0.71 muM) and of human AKR1B10 (Ki = 20.11 muM, 2.25 muM, 1.95 muM).	xanthohumol	22-24	latexin	Homo sapiens	144-147
29532688-3	2018	Our results show that XN, IX and 8-PN are potent uncompetitive, tight-binding inhibitors of human aldose reductase AKR1B1 (Ki = 15.08 muM, 0.34 muM, 0.71 muM) and of human AKR1B10 (Ki = 20.11 muM, 2.25 muM, 1.95 muM).	xanthohumol	22-24	latexin	Homo sapiens	144-147
29532688-3	2018	Our results show that XN, IX and 8-PN are potent uncompetitive, tight-binding inhibitors of human aldose reductase AKR1B1 (Ki = 15.08 muM, 0.34 muM, 0.71 muM) and of human AKR1B10 (Ki = 20.11 muM, 2.25 muM, 1.95 muM).	xanthohumol	22-24	latexin	Homo sapiens	144-147
30240731-6	2018	Furthermore, XN exposure triggered an increase in caspase-3 and caspase-7 activity, supporting its role in the activation of apoptosis.	xanthohumol	13-15	caspase 3	Homo sapiens	50-59
30240731-6	2018	Furthermore, XN exposure triggered an increase in caspase-3 and caspase-7 activity, supporting its role in the activation of apoptosis.	xanthohumol	13-15	caspase 7	Homo sapiens	64-73
30240731-8	2018	Altogether, our data show that XN induces the apoptosis of TPC-1 cancer cells in a concentration-dependent manner, suggesting XN to be a promising candidate for thyroid cancer therapy.	xanthohumol	31-33	two pore segment channel 1	Homo sapiens	59-64
30240731-8	2018	Altogether, our data show that XN induces the apoptosis of TPC-1 cancer cells in a concentration-dependent manner, suggesting XN to be a promising candidate for thyroid cancer therapy.	xanthohumol	126-128	two pore segment channel 1	Homo sapiens	59-64
30119200-0	2018	Xanthohumol induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI3K/Akt/mTOR-kinase in human gastric cancer cells.	xanthohumol	0-11	AKT serine/threonine kinase 1	Homo sapiens	98-101
30119200-0	2018	Xanthohumol induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI3K/Akt/mTOR-kinase in human gastric cancer cells.	xanthohumol	0-11	mechanistic target of rapamycin kinase	Homo sapiens	102-106
30119200-5	2018	XN induced phosphorylation of PI3K, Akt, and mTOR in SGC7901 cells.	xanthohumol	0-2	AKT serine/threonine kinase 1	Homo sapiens	36-39
30119200-5	2018	XN induced phosphorylation of PI3K, Akt, and mTOR in SGC7901 cells.	xanthohumol	0-2	mechanistic target of rapamycin kinase	Homo sapiens	45-49
29747239-9	2018	Xanthohumol (XN), a prenylated flavonoid extracted from the hop plant Humulus lupulus L. (Cannabaceae), significantly reduced cell invasion through inhibiting Stim1 expression.	xanthohumol	0-11	stromal interaction molecule 1	Homo sapiens	159-164
29747239-9	2018	Xanthohumol (XN), a prenylated flavonoid extracted from the hop plant Humulus lupulus L. (Cannabaceae), significantly reduced cell invasion through inhibiting Stim1 expression.	xanthohumol	13-15	stromal interaction molecule 1	Homo sapiens	159-164
29237346-4	2018	Xanthohumol (24 hours; 5 microM) behaved as an uncompetitive inhibitor of 14C-ARA uptake; the mammalian target of rapamycin, tyrosine kinases, and c-Jun N-terminal kinases intracellular pathways were involved in this effect; and it markedly reduced long-chain acyl-CoA synthetase 1 messenger RNA levels.	xanthohumol	0-11	acyl-CoA synthetase long chain family member 1	Homo sapiens	249-281
29237346-5	2018	Moreover, the effects of XN (24 hours; 5 microM) upon cell proliferation, culture growth, migration, viability, and apoptosis index were prevented by high extracellular ARA but not by the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist rosiglitazone.	xanthohumol	25-27	peroxisome proliferator activated receptor gamma	Homo sapiens	238-248
31595252-0	2019	Xanthohumol and 8-prenylnaringenin reduce type 2 diabetes-associated oxidative stress by downregulating galectin-3.	xanthohumol	0-11	lectin, galactose binding, soluble 3	Mus musculus	104-114
29906742-0	2018	Xanthohumol attenuates cisplatin-induced nephrotoxicity through inhibiting NF-kappaB and activating Nrf2 signaling pathways.	xanthohumol	0-11	NFE2 like bZIP transcription factor 2	Homo sapiens	100-104
29906742-6	2018	The levels of TNF-alpha, IL-1ss and IL-6 in kidney tissues were suppressed by xanthohumol.	xanthohumol	78-89	tumor necrosis factor	Homo sapiens	14-23
29906742-6	2018	The levels of TNF-alpha, IL-1ss and IL-6 in kidney tissues were suppressed by xanthohumol.	xanthohumol	78-89	interleukin 1 alpha	Homo sapiens	25-29
29906742-6	2018	The levels of TNF-alpha, IL-1ss and IL-6 in kidney tissues were suppressed by xanthohumol.	xanthohumol	78-89	interleukin 6	Homo sapiens	36-40
29906742-9	2018	Furthermore, the expression of TLR4 and the activation of NF-kappaB induced by cisplatin were significantly inhibited by xanthohumol.	xanthohumol	121-132	toll like receptor 4	Homo sapiens	31-35
29906742-10	2018	The expression of Nrf2 and HO-1 were dose-dependently up-regulated by the treatment of xanthohumol.	xanthohumol	87-98	NFE2 like bZIP transcription factor 2	Homo sapiens	18-22
29906742-10	2018	The expression of Nrf2 and HO-1 were dose-dependently up-regulated by the treatment of xanthohumol.	xanthohumol	87-98	heme oxygenase 1	Homo sapiens	27-31